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“Desafortunadamente, la naturaleza parece no percibir nuestra necesidad 
intelectual de conveniencia y unidad, y muy seguido se deleita en la complicación 
y la diversidad”  
(Unfortunately, nature seems unaware of our intellectual need for convenience 
and unity, and very often takes delight in complication and diversity) 
—Santiago Ramón y Cajal (1852 –1934)  
Pathologist, histologist, neuroscientist, and Nobel laureate 
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ABSTRACT 
Peptides generated from cellular protein degradation via the ubiquitin-proteasome 
pathway are presented on MHC class I as a means for the immune system to 
monitor polypeptides being synthesized by cells.  For CD8 
+
 T cells to prevent the 
spread of an incipient infection, it appears essential they should be able to sense 
foreign polypeptides being synthesized as soon as possible.  A prompt detection 
of viral proteins is of great importance for the success of an adaptive immune 
response.  Defective ribosomal products (DRiPs) have been postulated as a 
preferential source which would allow for a rapid presentation of peptides derived 
from the degradation of all newly synthesized proteins.  Although this hypothesis 
is intellectually appealing there is lack of experimental data supporting a 
mechanism that would prioritize presentation from DRiPs.  In this dissertation I 
describe a series of experiments that probe the DRiPs hypothesis by assessing the 
contribution to class I presentation of model epitopes derived from DRiPs or from 
functional proteins.  The results show that even at the early stages after mRNA 
synthesis DRiPs do not account for a significant fraction of the class I presented 
peptides.  These observations suggest that the currently widespread model 
whereby a mechanism exists which selectively allows for DRiPs to preferentially 
contribute to class I antigen presentation, is incorrect.  Rather, properly folded 
functional proteins can significantly contribute to class I antigen presentation as 
they are normally turned over by the ubiquitin-proteasome pathway.  
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CHAPTER I: INTRODUCTION 
 
 
1.1 The Identification of the Cytolytic T cell Ligands 
 
The fascinating history of the antigen presentation pathway commenced with the 
discovery of the immune response (Ir) genes (McDevitt & Tyan 1968; Bluestein et al. 
1971) and their linkage to the HLA and H-2 (Major Histocompatibility Complex [MHC] 
class I) loci in mice and humans (McDevitt & Tyan 1968; Levine et al. 1972).  The 
observation that T lymphocytes were able to specifically recognize and lyse target cells 
that had been exposed to antigens followed, and there was an intriguing requirement for 
these cytolytic T lymphocytes (CTLs) and their target cells to share their genotype in the 
mentioned H-2 loci (Doherty & Zinkernagel 1975; Zinkernagel & Doherty 1975; Bevan 
1975; Vitiello et al. 1989).  The manner in which these antigens were recognized in 
association with target cells leading to lymphocyte mediated lysis became a subject of 
great interest to the scientific community.   
 
  It was hypothesized that antigens were recognized by a T-cell receptor when they were 
displayed on the target cell surface in the context of the products of the H-2 loci 
(Schrader 1979).  How antigens were displayed to T-cells was still not fully understood.  
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Influenza proteins synthesized by cells made them targets for CTL lysis, and remarkably 
removing terminal fragments of the antigen sequence (Townsend et al. 1985) or 
removing the signal sequence that made the antigen inserted in the cell membrane did not 
impair lysis by CTLs (Townsend, Bastin, et al. 1986).  Therefore, antigens or fragments 
thereof were presented at the cell membrane in association with products of the H-2 locus 
and they needed not be integral membrane proteins. 
 
  A crucial experiment showed how cells could be sensitized to CTL lysis by incubating 
them with synthetic peptides as short as fifteen amino acids corresponding to a fragment 
of the antigen which the CTL were specific for (Townsend, Rothbard, et al. 1986).  This 
led to the belief that the antigens presented to CTLs may be a degradation fragment of 
intracellular proteins that was transported to the cell surface in association with MHC 
class I molecules (Townsend et al. 1985).  It was assumed that these fragments would 
derive from enzymatic digestion of the antigenic protein, as was the case with class II 
presentation to helper T cells (Ziegler & Unanue 1981).  The peptide association with 
MHC class I molecules was confirmed when the first crystal structure of a class I MHC 
molecule was obtained (Bjorkman et al. 1987).  A groove was apparent facing the 
extracellular milieu on the heavy chain of HLA, comprising a bed of antiparallel beta 
sheets flanked by two alpha helices.  The residues in this groove mapped to the regions of 
high polymorphism of the gene encoding the class I heavy chain (alpha 1 and 2).  In the 
crystal, this groove harbored a then unknown protein fragment: a short peptide.  Although 
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it was not confirmed at the time, it was already suggested that this peptide might be an 
antigenic epitope.  Previous experiments had shown that exogenous antigens were 
presented as peptides, and that they bound to MHC class II molecules on macrophages 
(Allen et al. 1984; Babbitt et al. 1985), so the observation of a peptide associated with 
MHC class I contributed to solidifying the model whereby the cytolytic T cells were 
recognizing fragments of foreign proteins associated with self molecules on the cell 
surface. 
 
 
1.2 Peptide Transport and Peptide-MHC class I Complex Formation 
 
MHC class I complexes are formed in the endoplasmic reticulum (ER), yet many 
antigens were known to be located in the cytosol: how can these antigens access the ER 
to bind class I molecules?  A set of experiments (Townsend et al. 1989) utilized 
exogenously provided viral peptides to promote class I heavy chain association with beta-
2-microglobulin—the light chain of the MHC class I complex (Grey et al. 1973)—in the 
ER of a cell (RMA-S) with a defect in surface class I levels (Ljunggren & Kärre 1985).  
It was through complementation studies in RMA-S (Powis et al. 1991) and in a human 
cell line also defective in surface class I (Spies & DeMars 1991) that for the first time 
functional evidence was obtained for a peptide transporter from the cytosol to the ER, 
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which was also encoded in the MHC cluster (Spies et al. 1990): the transporter associated 
with antigen processing (encoded by TAP1 and TAP2), as it would be later named.  
Further evidence for TAP functioning as a peptide translocator soon followed: the TAP 
homology to the ATP-binding cassette (ABC) family of transporters (Trowsdale et al. 
1990)—of which some members transport short peptides across membranes—together 
with competition experiments in which MHC class I complex formation was measured 
after adding peptides of different lengths (Shepherd et al. 1993), led to the belief that the 
antigens transported into the ER by TAP were eight to sixteen amino acid long peptide 
fragments.  Peptide transport was formally shown in vitro using microsome preparations 
(Lévy et al. 1991). 
 
 
1.3 The MHC Class I peptide ligands 
 
Throughout the years, the putative source of peptide ligands for MHC class I molecules 
has varied.  First it was assumed that any protein that was degraded would contribute to 
class I presentation.  The pepton hypothesis discussed below (Boon & Van Pel 1989) 
postulated the presented epitopes derived from transcription and translation of small 
DNA fragments.  The development of proteasome inhibitors led to the current belief that 
the vast majority of presented peptides are dependent on proteasome degradation (Rock 
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et al. 1994).  With some elements borrowed from the pepton hypothesis (Boon & Van Pel 
1989) the DRiPs hypothesis was postulated (Yewdell et al. 1996).  In the latter, defective 
polypeptides were introduced as a crucial source of epitopes that would solve the putative 
bias associated with the use of protein turnover as a supply.  The use of DRiPs also 
accommodated the requirement for proteasomal degradation.  Below I will describe in 
depth the features of each of the potential sources of MHC class I peptide ligands. 
 
 
1.4 MHC class I Presented Peptides as Products of Proteolysis 
 
In the quest to find a catalytic activity that may generate antigenic peptides, the ubiquitin-
proteasome pathway (Ciechanover et al. 1980; Hough et al. 1986; Fagan et al. 1987) was 
an appealing candidate, since it was known to be the major pathway for protein 
degradation in cells.  Proteasomes were clearly involved in the generation of the peptides 
presented on the MHC class I molecules (Rock et al. 1994).  Post-proteasomal peptide 
trimming was shown to take place not only in the ER as discussed above, but also in the 
cytosol (Towne et al. 2005; Towne et al. 2007; Towne et al. 2008; Kawahara et al. 2009). 
 
  All in all, these findings ranging from the genetic requirements for the cellular immune 
response, the TCR, the MHC class I complexes, and the peptides generated through 
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proteolysis supported a model where the generation of epitopes for presentation to CD8
+
 
T cells started with protein degradation. 
 
  Thus presented peptides were derived from the degradation of proteins by the 
proteasome, and it was assumed that mature protein turnover would provide the major 
source of peptides, and some subsequent experiments seemed to support this concept.  
Initial evidence for the contribution of mature protein turnover to class I presentation 
came from experiments in which mature foreign proteins were introduced into the cytosol 
of cells and class I presentation of peptides derived from them was monitored (Okada & 
Rechsteiner 1982; Moore et al. 1988; Grant et al. 1995).  MHC class I presentation was 
observed readily.  Although these results could not provide quantitative data—because 
the amount of protein introduced might have been overwhelming—they proved that the 
ubiquitin-proteasome degradation of stable proteins could be a source of peptide epitopes 
for class I presentation. 
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1.5 The Pepton Hypothesis 
 
As an alternative for the proteolytic origin of peptides bound to MHC class I molecules—
the pepton hypothesis—was postulated whereby the source of peptides for presentation 
would be transcription and translation of short DNA sequences within any given gene 
(Boon & Van Pel 1989).  This hypothesis arose from the puzzling observation that cells 
became sensitized to lysis by CTLs when transfected with small fragments of unspliced 
genes (Lurquin et al. 1989; Szikora et al. 1990).  If presented peptides were the product 
of protein proteolysis it would have been very unlikely that these cells became sensitized, 
since the gene fragment introduced did not have a promoter and it was severely truncated.  
The authors pointed at the possibility that a DNA dependent RNA polymerase specialized 
for antigen presentation had the ability to transcribe short stretches of DNA 
autonomously, i.e. without the need of a promoter sequence.  One advantage of this 
scenario is that all genes could be sampled whether or not their products were expressed.  
Another benefit derived from using peptons as opposed to protein degradation would be 
uniform sampling across the genome.  The proponents of the pepton hypothesis believed 
that if protein degradation were the main source of peptides from presentation, the 
epitopes on the cell surface would be heavily biased towards the most abundant proteins, 
leaving little or no representation for epitopes corresponding to less abundant proteins.  
On the other hand, that potential biased would be eliminated by using peptons as the 
source for MHC class I presented peptides.  This hypothesis did receive attention but 
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greatly lost impetus as experimental data started pointing at the proteasome as a major 
player in the generation of presented peptides.  
 
 
1.6 The DRiPs Hypothesis 
 
It was in the context of an acute viral infection that some (Yewdell et al. 1996) saw a 
paradox emerge from the findings discussed above.  From the teleological point of view, 
a search-and-destroy system that would efficiently prevent the spread of infection would 
want to eliminate the virus producing cells early, before the factories are in full swing, 
and thereby prevent a large number of virions from being produced.  A delay in detection 
would certainly be detrimental in controlling the infection, since the greater the number 
of virions produced by an infected cell before its destruction, the more likely it will be for 
neighboring cells to become infected.  Interestingly they noted, major epitopes identified 
as important for the lysis of infected cells by T cells were often derived from long-lived 
viral proteins.  Since the generation of MHC class I-presented epitopes was thought to 
occur as a result of protein turnover, it was assumed that long-lived viral proteins would 
require relatively longer times in order to be degraded, and hence sufficient peptide 
epitopes would not be obtained immediately upon infection; instead there would be a 
delay in presentation which would correlate with the epitope’s source-protein half-life.  
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This delay seemed to conflict with the observation that T cell induced lysis takes place 
shortly after infection of target cells, and therefore alternative sources of degradation 
products other than turnover of native proteins were sought after.  One such potential 
source was envisioned and termed Defective Ribosomal Products or DRiPs.  These 
would encompass aberrant protein species originating during—or very shortly after—
mRNA translation by ribosomes.  Quality control checkpoints are in place that detect and 
shunt defective ribosomal products into the ubiquitin-proteasome degradation pathway.  
Thus, DRiPs were deemed a fitting candidate for the source of MHC class I presented 
epitopes, since they would provide a peptide source readily after protein synthesis begins 
and their abundance would be independent of the half-life of the properly folded, 
functional proteins they failed to become.  This purported suitability of DRiPs as opposed 
to functional protein turnover at a later stage, led to a quest to identify and quantify 
DRiPs, and to correlate their availability with the levels of MHC class I antigen 
presentation.  Moreover, it was later postulated as a corollary, that there should be some 
kind of cellular machinery or compartment involved in the production of DRiPs that 
would enable a preferential usage of DRiPs- high levels of mRNA were already derived 
peptides over proper protein turnover derived peptides for loading onto MHC class I 
complexes. 
 
  The way in which DRiPs would dominate class I presentation has also evolved.  First it 
was postulated that DRiPs could provide only a small percentage of the presented 
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epitopes, the rest being provided by native protein degradation, and—under special 
circumstances such as viral infection—the levels of DRiPs could be up-regulated 
(Yewdell et al. 1996).  Later the fraction of DRiPs was quantified at over thirty percent of 
all synthesized polypeptides 
 
 
1.7 Experimental Support for DRiPs 
 
The initial experiments aimed at identifying and characterizing DRiPs revealed a large 
short-lived protein pool which labeled after [
35
S]-Methionine pulse in cells that had been 
starved and pre-treated with proteasome inhibitors (Schubert et al. 2000).  However, in a 
later report (Vabulas & Hartl 2005) the magnitude of this pool was ascribed to an artifact: 
the observed increase in radiolabel in cells treated with proteasome inhibitors was not due 
to the presence of  a short-lived protein pool being protected from degradation by the 
inhibitors, but rather to an increase in the relative incorporation of the radiolabeled amino 
acid—i.e. the specific activity—into those proteins.  As it turns out, when cells are grown 
in an amino acid deficient medium, they can sense a deficit in charged tRNAs, and they 
respond by inhibiting translation; even more so when they have been pre-treated with 
proteasome inhibitors.  In a radiolabeling experiment, this general reduction in translation 
results in an overall lower protein production, but the specific activity is enhanced.  What 
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was estimated by Schubert et al. to be a DRiP fraction of one third of the total 
synthesized protein, Vabulas and Hartl reduced to a few percent at most in their 
experiments, when a comparison of specific activity was made between samples with or 
without amino acid deficient medium pre-treatment. 
 
  The empirical support for DRiPs as a major source of peptides for antigen presentation 
was eloquently summarized in a publication title “Tight Linkage between Translation and 
MHC Class I Peptide Ligand Generation Implies Specialized Antigen Processing for 
Defective Ribosomal Products” (Qian, Reits, et al. 2006).  Indeed, the addition of protein 
synthesis inhibitors resulted in a nearly complete stall in antigen presentation, despite the 
continued presence of mature protein in the cells. In other words, this finding was 
consistent with the source of presented peptides being newly synthesized proteins rather 
the pool of older proteins.  Nevertheless, there was the question of whether protein 
synthesis inhibition could have global effects, affecting processes other than the 
generation of peptides.  
 
  Another study used an innovative technique to measure the rate of peptide supply to the 
loading complex in the ER (Reits et al. 2000).  A subunit of TAP (TAP1) was fused to 
GFP and its mobility along the ER membrane was measured.  A diffusion coefficient was 
obtained by bleaching a spot on the ER with a laser and imaging the recovery of GFP 
fluorescence following bleaching using confocal microscopy.  TAP mobility was found 
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to be inversely proportional to the rate of peptide transport.  Using this methodology, the 
peptide transport rate was compared in the presence or absence of protein synthesis 
inhibitors.  The conclusion was that the majority of the TAP substrates were derived from 
newly synthesized proteins, which is in accordance with the DRiPs hypothesis. 
 
 
1.8 Examples of DRiPs-derived Antigens 
 
There are a number of reports where the generation of individual epitopes is shown to be 
linked to the source protein’s translation.  Of the seven known class I epitopes derived 
from the lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP) in the mouse, 
only one has been examined and found to be linked to protein neosynthesis (Khan et al. 
2001).  Two class I epitopes from Epstein-Barr virus nuclear antigen (EBNA) were 
shown to be readily presented in the early phase of antigen expression, but their 
presentation declined after protein synthesis ceased (Mackay et al. 2009).  In another 
study (Voo et al. 2004), response by CD8
+
 T cell clones to 293T cells transfected with 
EBNA1 was blocked by protein synthesis inhibitors.  Therefore, although few, there are 
examples of viral epitopes whose presentation is linked to the synthesis of its source 
protein. 
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1.9 Cellular Protein Synthesis Shutdown 
 
As described in the previous sections, the DRiPs model is greatly supported by data 
establishing a link between mRNA translation and MHC class I antigen presentation.  
This link was established through experiments using protein synthesis inhibitors.  It is 
worth mentioning that upon viral infection and in response to signals such as the presence 
of double stranded RNA (Leaman et al. 1998), cells can respond by shutting off protein 
synthesis as a way of preventing viral spread.  The presence of interferon also leads to 
cellular shutoff or to apoptosis (Stark et al. 1998). 
 
The virus-mediated inhibition of protein synthesis cannot be complete, since the virus is 
an obligate parasite, but there are mechanisms that lead to a partial cellular protein 
synthesis shutoff while allowing virally encoded proteins to continue being synthesized.  
This partial shutoff of cellular protein synthesis is advantageous for the virus, since it 
diverts the synthesis machinery to its own proteins while keeping the host cell alive.  
Viruses can adopt countermeasures to gain access to the cellular protein synthesis 
machinery and divert translation to their own mRNAs: for example, adenoviruses (Huang 
& Schneider 1990) and influenza virus (Feigenblum & Schneider 1993) can promote 
dephosphorylation of eIF4E, thus preventing cap-mediated translation initiation, which is 
essential for cellular transcripts but not for viral protein synthesis (Dolph et al. 1990). 
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  In situations where cells are infected with viruses that direct translation towards their 
own mRNAs, most of the cellular DRiPs would rapidly wane, leaving chiefly viral DRiPs 
available for processing and presentation. 
 
 
1.10 Mechanisms of DRiPs as a Preferential Source for Presentation 
 
The neo-synthesis data that was used to support DRiPs as the major source of presented 
peptides suggested that mature proteins were excluded from the presentation pathway or 
were presented very inefficiently: this is counterintuitive, since mature proteins are still 
degraded by the ubiquitin-proteasome pathway.  Why would they not be presented?  
They should be, especially since cytosolic peptides from loaded exogenous proteins or 
synthesized from minigenes are readily presented.  For this preference for DRiPs to 
operate, additional mechanisms had to be postulated.  If DRiPs are to be preferentially 
utilized as a source, there must be some kind of compartmentalization at the translation 
level.  Once more, like in the DRiPs hypothesis paper (Yewdell et al. 1996), another 
review (Yewdell & Nicchitta 2006) pointed out the future experiments that will, in the 
authors’ opinion, support their pre-conceived idea that DRiPs are the major source of 
class I presented peptides.  Several possibilities are described: 1) “immunoribosomes” 
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that have the ability to translate recently synthesized mRNAs (marked by different cap 
and polyA-binding protein) and are more error-prone than conventional ribosomes 2) ER-
associated ribosomes 3) mRNAs degraded after the pioneer round of translation in the 
nucleus in the context of nonsense-mediated decay.  HLA-encoded tRNAs that might be 
more prone to charging the wrong amino acid was also proposed to contribute to 
deliberate DRiP generation for immune surveillance purposes.  As of today there is very 
little evidence for immunoribosomes, and none for rough ER ribosomes being more 
error-prone.  Below are the details of the published attempts made to identify possible 
elements of this postulated compartmentalization. 
 
  A modulation of the accuracy of translation could represent a mechanism of DRiP 
induction by augmenting DRiP production in infected cells.  It is hard to envision a way 
of compartmentalizing translation accuracy so that the fidelity would be as good as 
possible for regular translation and more error-prone for DRiP translation.  A global 
decrease in fidelity in infected cells might allow for an increase in DRiPs, and although 
the side effects would be detrimental for the cell’s health, it would not be a problem since 
it is destined to die after alerting the immune system to the infection.  To examine this 
possibility tRNAs isolated from cells infected with different viruses were compared with 
those from uninfected cells (Netzer et al. 2009).  The effects of viral infection on Met-
tRNA misacylation were rather small—in most cases there was an increase from <0.1% 
to 0.1-0.4% of tRNAs wrongly charged with methionine (the fold-increase cannot be 
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determined since the data are given as a range).  The authors claim that this increase 
would lead to a significantly greater DRiP rate by virtue of a higher likelihood of 
misfolding shortly after protein synthesis due to amino acid misincorporation, thus 
contributing to an increase in class I antigen presentation. 
 
 
  With regards to the aforementioned “immunoribosomes”, a possible candidate took the 
spotlight: a set of ribosomes that specifically scans for alternative translation initiation 
sites.  Shastri and colleagues found a mechanism that could explain the observation of 
cryptic reading frame epitopes (Malarkannan et al. 1999), whereby translation initiation 
occurred from codons other than AUG, i.e. not encoding methionine (Schwab et al. 
2004).  They used T-cell hybridomas as a readout for peptides initiated at CUG (encoding 
leucine as the N-terminal amino acid).  They observed that translation could start at CUG 
and it was not hindered by the presence of AUG sites upstream and out of frame.  This 
phenomenon was interpreted as the existence of a subpopulation of ribosomes that 
specifically scans for CUG instead of AUG.  Interestingly, CUG initiation was enhanced 
when the eukaryotic initiation factor 2α (eIF2α) was phosphorylated, which occurs as a 
result of many types of viral infections (Sonenberg 2000, chap.31–35) and of cellular 
stress (Sonenberg 2000, chap.15).  This would support the idea that upon infection or 
during situations of cellular stress, aberrant translation products resulting from incorrect 
initiation events would become more abundant, thus leading to a greater amount of 
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DRiPs.  In addition non-AUG initiation has been observed in retroviruses, such as human 
T-cell lymphotropic virus, in which it allows for in-frame expression of regulatory 
proteins (Corcelette et al. 2000). 
 
  Support for compartmentalization of preferential substrates for MHC class I 
presentation came from the observation that peptides encoded as ubiquitin fusions—
which are liberated in the cytosol by ubiquitin hydrolase activity, rather than by 
degradation of the source protein by the ubiquitin-proteasome pathway—did not compete 
for MHC class I binding with peptides encoded as NP fusions, which are liberated by the 
proteasome (Lev et al. 2010). 
 
  An enticing compartmentalized source of DRiPs is the nucleus.  Inhibiting viral mRNA 
transport from the nucleus to the cytosol led to a lower than expected reduction in antigen 
presentation, suggesting nuclear translation was an important contributor to MHC class I 
presented epitopes (Dolan et al. 2010).  The inhibition of viral mRNA transport to the 
cytosol led to a substantial decrease in viral protein levels, as expected.  However the 
magnitude of the decrease in protein expression was not matched by the reduction in 
antigen presentation.  This was taken to imply that the contribution of viral proteins 
synthesized in the nucleus was greater than the contribution by the products of cytosolic 
translation.  Nevertheless, this initial observation led to an interest in nuclear translation, 
in particular, in the non-sense mediated decay of RNA pathway.  This is a quality control 
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mechanism whereby a pioneer round of translation takes place from the pre-mRNA still 
associated with splicing machinery components in the nucleus.  If protein synthesis 
terminates upstream of the 3’ splice junction, a cascade is triggered that leads to the 
degradation of the pre-mRNA before it can mature and exit the nucleus.  In order to test 
whether the products of this pioneer round of translation contribute to class I antigen 
presentation, a model epitope was encoded upstream of a cDNA encoding a termination 
codon 5’ of a splice junction (Apcher et al. 2011).  Indeed the model epitope was 
presented in transfected cells, and the levels of presentation were close to those in cells 
transfected with control constructs.  
 
 
1.11 Post-proteasomal Processing 
 
Peptides were recovered from ternary complexes with MHC class I heavy chain and beta-
2-microglobulin, and their sequence matched that of full-length cellular (Wallny & 
Rammensee 1990) or non-self (Townsend et al. 1985) proteins.  However, the length of 
the isolated peptides ranged mostly from eight to ten amino acids (Van Bleek & 
Nathenson 1990; Falk et al. 1991).  TAP could transport peptides this size, but longer 
peptides were transported as well.  These longer precursor peptides were soon shown to 
be trimmed in the ER after being transported by TAP in order to fit the class I heavy 
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chain peptide binding motif (Roelse et al. 1994).  It would take longer, though, until the 
identification and characterization of the enzymatic activities responsible for this 
trimming process in the ER (Serwold et al. 2002; York et al. 2002; Saveanu et al. 2005; 
Georgiadou et al. 2010). 
 
 
1.12 Scope of Thesis 
 
The work described in this dissertation is aimed at assessing the contribution of different 
sources of peptides to MHC class I antigen presentation.  DRiPs have been postulated as 
a dominant or exclusive contributor to this pathway.  Since the evidence for the DRiPs 
model was far from conclusive, it became apparent that the key to elucidating which, if 
any, of the two sources of peptides—DRiPs or mature proteins—was the major 
contributor to MHC class I presentation was a direct comparison between substrates 
which could specifically yield peptides from one or the other source.  The experiments 
presented in this dissertation will compare the contribution of a model substrate which 
can yield epitopes from both folded and misfolded species, relative to that of another 
model substrate which can yield epitopes exclusively from properly folded species by 
virtue of a post-translational self-catalytic process which requires an appropriate tertiary 
structure: protein splicing. 
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1.13 Intein Catalysis 
 
An intein is a domain within a polypeptide that can splice, leaving re-ligated flanking 
domains, known as exteins.  This occurs by a self-catalytic process that does not require 
any other proteins (Figure 1.4).  There are many examples of inteins in nature, mostly in 
single cell organisms (prokaryotes and eukaryotes) (Perler 2002).  Inteins are believed to 
have originated as “selfish genetic elements”, since they possess homing endonuclease 
activity (Dujon et al. 1986; Bremer et al. 1992).  They are encoded by mobile genetic 
elements that are transmitted to the progeny at rates higher than expected from Mendelian 
inheritance, as they insert via duplicative transposition.  Homing endonucleases are 
selected so they do not interfere with coding sequences in the host genome.  They can be 
found in intergenic sequences, introns, and when they intervene coding sequences, they 
are associated with inteins, so the gene product they intervene is still produced normally 
after translation and intein splicing.  A mini-intein is an intein in which the homing 
endonuclease coding sequence has been removed and the minimal elements required for 
splicing are retained (Figure 1.1). 
 
  Two amino acids—threonine and histidine—in the conserved N3 domain, also known as 
“Motif B” of inteins are crucial for splicing (Ghosh et al. 2001).  Remarkably, this 
domain is far from the splicing ends in the primary structure, and these amino acids only 
come close together with the splicing sites when the intein attains its native three-
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dimensional structure (Klabunde et al. 1998).  Enzymatic mechanisms have been 
proposed (Klabunde et al. 1998; Ding et al. 2003) where the histidine in the N3 domain is 
involved in the N-S acyl shift that takes place as the first step in intein catalysis as shown 
in Figure 1.4.  Both the histidine in the N3 domain and a threonine residue N-terminal of 
it (positions 73 and 51 in the Synechocystis sp. DnaB sequence) contribute to stabilizing 
the intermediate during the N-S acyl shift step (Ding et al. 2003)  The full length RecA 
intein from Mycobacterium tuberculosis (Mtu RecA) crystal structure (Van Roey et al. 
2007) also predicts a close arrangement between the splicing sites and the histidine in the 
N3 domain (Figure 1.2), in spite of these amino acids being far apart in the primary 
sequence (Figure 1.3). 
 
  Therefore, the requirement to attain tertiary structure in order for splicing to occur 
makes inteins an excellent tool to distinguish folded, functional protein species from 
those that are misfolded or that have not yet acquired their native structure. 
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Figure 1.1  Position of the homing endonuclease and conserved residues in inteins.  
Summarized diagram of a typical intein showing the residue requirement at the intein-
extein junction and at the N3 domain.  In a mini intein (bottom) the homing endonuclease 
activity is removed and the residues involved directly or indirectly in the splicing 
catalysis remain.  Modified from (Perler 2002) 
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Figure 1.2  Diagram of the crystal structure of the M. tuberculosis RecA mini-intein 
(Van Roey et al. 2007).  Highlighted in black are the terminal residues and the histidine 
side chain in the N3 block, all of which are involved in catalysis.  Made with PyMol 
software (Delano Scientific, Palo Alto, CA) using the data deposited in the Protein Data 
Bank, ID 2imz (Van Roey et al. 2007). 
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Figure 1.3  Clustal W (Thompson et al. 1994) alignment of the amino acid sequences 
of the M. tuberculosis and P. chrysogenum mini-inteins used.  The regions involved in 
the splicing catalysis are highlighted in black.  
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Figure 1.4  Enzymatic mechanisms proposed for intein catalysis Modified from 
(Klabunde et al. 1998; Ding et al. 2003).  The histidine in the N3 block appears hydrogen 
bonded to the amino group on the N-splicing site.  The different steps proposed for 
catalysis are shown: N-S acyl shift, transesterification, asparagine cyclization and O-N 
shift.  
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CHAPTER II: MATERIALS AND METHODS 
 
2.1 Cell Lines, Hybridomas and T Cells 
 
All cell lines were grown in a tissue culture humidified incubator at 37 °C and 5% CO2 in 
RPMI-1640 supplemented with 10% FCS, 100 µM Non-essential amino acids, 1 mM 
sodium pyruvate, 2 mM L-glutamine, 0.25 µg/ml Amphotericin B, 50 U/ml Penicillin G, 
50 µg/ml Streptomycin Sulfate, 55 µM 2-ME, 10 mM HEPES 
 
  E36 cells were selected as the target cells for antigen expression.  E36 cells are an 
established cell line derived from Chinese hamster lung carcinoma (Gillin et al. 1972).  
Murine H-2D
b
 and ICAM1 were previously transfected into E36 cells and stable 
transfectants were selected (E36.17.3 or E36/D
b
) (Mo et al. 1999).  These cells were 
infected with a lentivirus encoding H-2K
b
 to yield E36/K
b
D
b
 (hereafter E36). 
 
  The AN9-D
b
-specific 12.64 hybridoma was provided by Dr. David Woodland (Trudeau 
Institute, Saranac Lake, NY).  This hybridoma has been shown to recognize 
ASNENMETM and not CSNENMETM as its cognate peptide in the context of H-2D
b
 
(Sigal & Wylie 1996).  This is important, since detection of CSNENMETM would defeat 
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the purpose of recognizing exclusively peptides derived from spliced species, as the 
degradation of an unspliced intein-containing protein could generate CSNENMETM.  
12.64 cells were transduced first with a retrovirus encoding the mouse CD8-alpha chain 
(Lyt-2a) cDNA downstream of an IRES (Levkau et al. 2001).  The retrovirus was 
packaged using the plasmid pBMN-IRES-Lyt-2a, a generous gift from Dr. Elaine Raines 
(University of Washington, Seattle, WA).  After selection, the resulting line was infected 
with a lentivirus encoding the mouse CD8-beta chain in the pTRIPZ plasmid vector 
(Open Biosystems, Lafayette, CO).  After selection, yet another round of lentiviral 
transduction was performed, this time the vector encoded a minimal promoter containing 
NFAT binding sites upstream of a luciferase ORF (NFAT-Luc cassette).  The final line is 
12.64-CD8αβ-Luc (hereafter 12.64).  
 
  The NFAT-Luc cassette lentivirus was generated by Freidrich Cruz, UMass Medical 
School, Department of Pathology.  It was subcloned from pGL3-NFAT32 (Addgene, 
Cambridge, MA) along with the bsd
R
 ORF driven by the SV40 promoter from pCDNA6 
(Invitrogen, Carlsbad, CA), into the lentiviral vector pCDH1 (Systems Biosciences), 
replacing the CMV promoter. The resulting plasmid, pCDH1-NFAT-Luc-Bsd was 
transcribed in 293T cells and packaged into VSV-G pseudotyped lentivirus. 
 
  The SL8-K
b
-specific RF33-Luc (hereafter RF33) was derived from the RF33 T cell 
hybridoma which recognizes SIINFEKL in the context of H-2 K
b
 (Rock et al. 1990).  
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These cells were also transduced with the NFAT-Luc cassette described above.  This cell 
line was generated by Kenneth Rock and Freidrich Cruz, UMass Medical School, 
Department of Pathology. 
 
  Spleens from female HY (Jarid1d, also called Smcy) TCR transgenic mice (Kisielow et 
al. 1988) in the C57BL/6 background (a kind gift of Dr. Raymond Welsh, UMass 
Medical School Department of Pathology) were used as a source of HY-D
b
-specific 
CD8
+
 T cells. 
 
 
2.2 Molecular Cloning 
 
See a schematic diagram of the constructs used in the experiments on Figure 3.6.  All 
constructs were analyzed for correct insertion and sequenced.  Restriction enzyme and 
Calf Intestinal Phosphatase treatment was performed according to the manufacturer’s 
instructions (New England Biolabs, Ipswich, MA).  RNA extraction, plasmid 
purification, PCR cleanup, and purification from agarose gel electrophoresis were 
performed using Qiagen’s (Valencia, CA) nucleic acid purification kits.  PCR for cloning 
was performed with the Platinum Pfu polymerase kit (Invitrogen, Carlsbad, CA); and for 
E. coli colony screening, with the Taq polymerase kit (Invitrogen, Carlsbad, CA).  DNA 
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ligations were performed at different insert to vector ratios using T4 DNA ligase 
(Invitrogen, Carlsbad, CA).  For cloning into pCDNA (Invitrogen, Carlsbad, CA), DH5α 
subcloning efficiency competent E. coli were used for transformation of ligated products 
(Invitrogen, Carlsbad, CA), and cells were plated on LB-Miller broth agar petri dishes 
with 100 µg/mL ampicillin (Sigma, Saint Louis, MO).  For cloning into pTRIPZ (Open 
Biosystems, Lafayette, CO), XL-10 gold ultracompetent E. coli were used for 
transformation of ligated products (Stratagene, Agilent Technologies, Santa Clara, CA), 
and cells were plated on LB-Lennox broth (NaCl 5 g/L) agar petri dishes with 100 µg/mL 
ampicillin (Sigma, Saint Louis, MO) and 25 µg/mL. 
 
The PCR routine used was as follows: 94°C    2 min 
   94°C  30 s 
       50-55°C  30 s      x 30 cycles 
       72°C  1 min/kilobase pair 
       72°C  5 min 
         4°C  ∞ 
 
Construct No. 1 (a & b): pCDNA-GFP-Int-A9M. Precursor of GFP-PRP8-A9M 
Sequence: (GFP)-SIINFEKL-A-(Pch PRP8)-SNENMETM-DS-(HA tag) 
PCR 1.1 
Template: pGPch-1, encoding the Pch PRP8 intein (Stephanie Pöggeler) 
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Forward Primer: S8L PRP8 Fwd 
Reverse Primer: TP Rev 
PCR 1.2 
Template: pGPch-1 (Stephanie Pöggeler) 
Forward Primer: TPNH Fwd for wild-type (a) or tpnl Fwd for N3 mutant (b) 
Reverse Primer: PRP NP Rev 
PCR 1.3 (a, wild-type; b, N3 mutant) 
Template: Ligation of PCRs 1.1a or b, and PCR 1.2, both after SpeI digestion 
Forward Primer: S8L PRP8 Fwd 
Reverse Primer: NP HA Xba Rev 
Construct No. 2 (a & b): pCDNA-GFP-PRP-A9M: same as above, but inserting a short 
peptide from natural N-extein (GSFWEK) to enhance splicing efficiency. 
Sequence: (GFP)-SIINFEKL-GSFWEK-A-(Pch PRP8)-SNENMETM-DS-(HA tag) 
PCR 2.1 (a, wild-type; b, N3 mutant) 
Template: precursor construct No. 1 PCR 1.3 a or b (see above) 
Forward Primer: S8L PRP 2 Fwd 
Reverse Primer: NP HA Xba Rev 
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PCR 2.2  
Template: pEGFP-C1 (Clontech, Mountain View, CA) 
Forward Primer: GFP Kpn Fwd 
Reverse Primer: GFP S8L H3 Rev 
PCR product 2.1 was digested with HindIII and XbaI 
PCR product 2.2 was digested with KpnI and HindIII  
Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR products 2.1 and 2.2 were ligated with digested vector to generate 
pCDNA-GFP-PRP-A9M wild-type or N3 mutant. 
Construct No. 3: GFP-NP: pre-spliced (no intein) version of construct No. 2 
Sequence: (GFP)-SIINFEKL-GSFWEK-ASNENMETM-DS-(HA tag) 
PCR 3.1 
Template: PCR 2.1 
Forward Primer: Fus NP Fwd 3 
Reverse Primer: NP HA Rev 
PCR product 2.1 was digested with HindIII and XbaI  
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Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR products 3.1 and 2.2 were ligated with digested vector to generate 
pCDNA-GFP-A9M. 
Construct No. 4: pCDNA-GFP-Int-K9L. Precursor of GFP-Rec-K9L. 
Sequence: (GFP)-(Mtu RecA)-CSRNRQYL-(HA tag) 
PCR 4.1 
Template: pEGFP-C1 (Clontech, Mountain View, CA) 
Forward Primer: GFP Kpn Fwd 
Reverse Primer: gint Rev 
PCR 4.2 
Template: pGFPmU, encoding the Mtu RecA intein (Henry Paulus) 
Forward Primer: Gint Fwd 
Reverse Primer: Int SMCY Rev 
PCR 4.3 
Template: 0.1 µL of PCRs 4.1 and 4.2 
Forward Primer: GFP Kpn Fwd 
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Reverse Primer: Int SMCY Rev 
PCR 4.4 
Template: PCR 4.3 
Forward Primer: GFP Kpn Fwd 
Reverse Primer: SMCY HA Rev 
PCR product 4.4 was digested with KpnI and XbaI. 
Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR product 4.3 was ligated with digested vector to generate pCDNA-GFP-Int-
K9L. 
Construct No. 5:  pCDNA-GFP-Rec-K9L.   
Sequence: (GFP)-SIINFEKL-DEY-K-(Mtu RecA)-CSRNRQYL-(HA tag) 
PCR 5.1 
Template: pGFP-SICNFEKL (Made before) 
Forward Primer: CMV Fwd 
Reverse Primer: GFP S8L H3 Rev 
PCR 5.2 
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Template: pCDNA-GFP-Int-K9L  
Forward Primer: S8L H3 Fwd 
Reverse Primer: SMCY HA Rev 
PCR 5.3 
0.1 µL of PCRs 5.1 and 5.2 
Forward Primer: GFP Kpn Fwd 
Reverse Primer: SMCY HA Rev 
Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR product 4.3 was ligated with digested vector to generate pCDNA-GFP-
Rec-K9L. 
Construct No. 6: pCDNA-GFP-Rec-K9L N3 mutant version (does not splice).   
Sequence: (GFP)-SIINFEKL-DEY-K-(N3 mutant Mtu RecA)-CSRNRQYL-(HA tag) 
PCR 6.1 
Template: Construct No. 5, pCDNA-GFP-Rec-K9L. 
Forward Primer: CMV Fwd 
Reverse Primer: N3 RecA mut Rev 
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PCR 6.2 
Template: Construct No. 5, pCDNA-GFP-Rec-K9L. 
Forward Primer: N3 RecA mut Fwd 
Reverse Primer: SMCY HA Rev 
PCR 6.3 
Template: 0.1 µL of PCRs 6.1 and 6.2 
Forward Primer: CMV Fwd 
Reverse Primer: Int SMCY Rev 
Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR product 4.3 was ligated with digested vector to generate pCDNA-GFP-
Rec-K9L N3 mutant 
Construct No. 7: pCDNA-GFP-K9L.  Pre-spliced version of construct No 5. 
Sequence: (GFP)-SIINFEKL-DEY-KCSRNRQYL-(HA tag) 
PCR 7.1 
Template: Construct No. 5, pCDNA-GFP-Rec-K9L. 
Forward Primer: CMV Fwd 
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Reverse Primer: Fus HY Rev 
PCR 7.2 
Template: PCR 7.1 
Forward Primer: CMV Fwd 
Reverse Primer: Int SMCY Rev 
Vector: pCDNA 3.1 Hygro (Invitrogen, Carlsbad, CA) was digested with KpnI and XbaI 
and treated with calf intestinal phosphatase (New England Biolabs, Ipswich, MA). 
Digested PCR product 4.3 was ligated with digested vector to generate pCDNA-GFP-
K9L. 
 
pTRIPZ lentiviral vector (Open Biosystems, Lafayette, CO): This vector provides a 
lentiviral backbone along with two expression cassettes: one for the reverse tetracycline 
transactivator, and another one for RFP (red fluorescent protein) and micro RNA 
expression driven by a doxycycline-inducible CMV minimal promoter.  The RFP and 
micro RNA regions in pTRIPZ were removed by digesting with AgeI and MluI restriction 
enzymes and purifying the vector fragment from an agarose gel.  Constructs No. 2 a & b, 
3, 5, 6, and 7 were used as templates for PCR reactions to introduce AgeI and MluI 
restriction sites.  Primers were GFP Age Fwd and BGH Mlu Rev.  The ORFs contained 
the construct and a BGH poly(A) signal from pCDNA 3.1.  These PCR products were 
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digested with AgeI and MluI restriction enzymes and ligated to the digested vector treated 
with calf intestinal phosphatase (New England Biolabs, Ipswich, MA).  The resulting 
plasmids were sequenced using the GFP Age Fwd and BGH Mlu Rev primers, and the 
correct clones were selected and plasmid DNA was amplified and purified. 
 
  The Mtu RecA mini-intein encoding plasmid (pGFPmU) was a generous gift from Dr. 
Henry Paulus (Boston Biomedical Research Institute, Watertown, MA) (Gangopadhyay 
et al. 2003).  The Pch PRP8 mini-intein encoding plasmid (pGPch-1) was kindly 
provided by Dr. Stephanie Pöggeler (Georg-August-Universität Göttingen, Göttingen, 
Germany) (Elleuche et al. 2008). The GFP encoding sequence was amplified from 
pEGFP-C1 (Clontech, Mountain View, CA), which encodes a modified Aquoera victoria 
GFP.  The pCDH lentivirus expression vector (System Biosciences, Mountain View, CA) 
encoding  H-2K
b
 was provided by Freidrich Cruz (UMass Medical School, Worcester, 
MA).  
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Table 2.1: Primer list 
Primer 
Name 
5' to 3' Sequence 
BGH Mlu Rev GGCACGCGTAGCCCACCGCATCCCCAGC 
CMV Fwd CGCAAATGGGCGGTAGGCGTG 
Fus HY Rev 
TAAGTACTGTCGATTCCTTGAACACTTGTACTCGTCAAGCTTCTCAAAGTTGATGA
TACTC 
Fus NP Fwd 3 GGCGAAGCTTGGATCCTTCTGGGAGAAAGCGAGTAACGAAAACATGGAAACTATG 
GFP Age Fwd CGGACCGGTCGCCACCATGGTGAGCAAGGGCG 
GFP Kpn Fwd GAGCGGTACCGCCACCATGGTGAGCAAGGGCGAGGAGC 
GFP S8L H3 Rev GCTCTAGATTAAAGCTTCTCAAAGTTGATGATACTC 
Gint Fwd CTGTACAAGTGCCTCGCAGAGGGCACCCGAATC 
gint Rev CTCTGCGAGGCACTTGTACAGCTCGTCCATGCC 
Int SMCY rev AACGTAAGTACTGTCGATTCCTTGAACAGTTGTGCACGACAACCCCTTC 
N3 RecA mut 
Fwd 
TGTGGGCGACACCCGATCTTAAGGTGCT 
N3 RecA mut 
Rev 
AAGATCGGGTGTCGCCCACAC 
NP HA Xba Rev 
GCTCTAGATTAAGCGTAATCTGGAACGTCATATGGATAGCTGTCCATAGTTTCCAT
GTT 
PRP NP rev CATAGTTTCCATGTTTTCGTTACTGTTGTGCAGGACAAGGTAGTC 
S8L H3 Fwd GAGAAGCTTGACGAGTACAAGTGCCTCGCAG 
S8L PRP 2 Fwd CCCCAAGCTTGGATCCTTCTGGGAGAAAGCGTGTCTCGCCAAGGGGACC 
S8L PRP8 Fwd CCCCAAGCTTGCGTGTCTCGCCAAGGGGACC 
SMCY HA rev 
GCTCTAGATTAAGCGTAATCTGGAACGTCATATGGATAACGTAAGTACTGTCGATT
CCTTGAAC 
TP Rev GGGGACTAGTTCCTCTTTCTCACCGCCGATC 
TPNH Fwd GGGGGAACTAGTGGTGACGCCGAACCATATTC 
tpnl fwd GGGGGAACTAGTGGTGACGCCGAACCTGATTC 
 
Table 2.1: Primer list.  DNA primers used for molecular cloning and sequencing 
(alphabetically listed).  
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2.3 Retrovirus and Lentivirus Packaging 
 
VSV-G pseudotyped lentivirus particles were generated by co-transfecting the lentiviral 
vector with a lentivirus packaging mix (Open Biosystems, Lafayette, CO) into LentiX 
293T cells (Clontech, Mountain View, CA). The packaging mix contains seven HIV-1 
genes (gag, pro, vpr, rt, in, tat, rev) in three different plasmids (pTLA1-Pak, pTLA-1-
Enz, pTLA1-Tat/Rev).  The HIV-1 envelope gene is substituted by the VSV-G encoding 
gene, therefore the resulting virions were pseudotyped, which conferred them a much 
broader tropism than that of HIV-1 (Gilden et al. 1981).  Seventy-two hours after 
transfection supernatants were collected and concentrated by 20,000 xg 
ultracentrifugation in an SW28 rotor (Beckman Coulter, Indianapolis, IN).  Pellets were 
resuspended in 0.5 mL PBS.  In order to calculate the virus titer, RNA copy number in 
supernatants was obtained using quantitative PCR.  RNA extraction was performed from 
50 µL of resuspended pellets using the QIAamp Viral RNA Mini Kit purification kit 
(Qiagen, Valencia, CA).  RNA was reverse-transcribed into single strand DNA using the 
iSCRIPT kit with random hexamer primers (Bio-Rad, Hercules, CA).  Copy number was 
determined using a TaqMan® assay with primers and fluorescein labeled probes specific 
for the enhanced GFP gene (“EGFP All”, Applied Biosystems, Foster City, CA).  Serial 
dilutions of GFP containing plasmid DNA were used as a standard. 
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  The PCR routine was as follows:  95°C    10 min 
95°C    15 s 
           x 40 cycles 
    60°C   1 min   
 
  VSV-G pseudotyped retrovirus particles were generated by transfecting pBMN-IRES-
Lyt2a (Levkau et al. 2001) into Phoenix GP cells, which expresses only murine leukemia 
virus gag-pol and VSV-G.  Seventy-two hours after transfection supernatants were 
collected and concentrated by 20,000 xg ultracentrifugation in an SW28 rotor (Beckman 
Coulter, Indianapolis, IN).  Pellets were resuspended in 0.5 mL PBS. 
 
 
2.4 Infection and Cell Purification 
 
E36 cells were cultured overnight in RPMI-1640 10% FCS in 12 well plates so they will 
be in logarithmic growth phase the next morning. Infection with retrovirus or lentivirus 
was performed in the presence of polybrene (SIGMA, St Louis, MO) at 10 µg/mL.  The 
inoculum varied depending on the titer.  Although not always possible, the preferred 
multiplicity of infection was five to ten.  Titers were estimated or calculated as shown 
above.  Seventy-two hours later infected cells were purified to at least 90% purity by 
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positive selection after overnight induction with 1 µg/mL doxycycline.  For positive 
selection cells were detached with trypsin EDTA, neutralized and washed, and stained 
with either 25-D1.16 antibody (Porgador et al. 1997) or biotin-conjugated anti-mouse 
CD8α (clone 53-6.7, BD biosciences, San José, CA)  in PBS containing 2% FCS and 2 
mM EDTA followed by a wash step and binding to 5 µm Dynal beads (Invitrogen, 
Carlsbad, CA) conjugated to goat anti-mouse IgG or to streptavidin according to the 
manufacturer’s instructions (Dynabeads Pan mouse IgG or Dynabeads M-280 
Streptavidin, Invitrogen, Carlsbad, CA).  Cells were washed twice using a Dynamag 
magnet according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA) and 
returned to culture.  The purified E36 cells were maintained in G418 and monitored for 
H-2K
b
, H-2D
b
, and ICAM-1 expression by flow cytometric staining.  The monoclonal 
antibodies used for staining were AF6-88.5, KH-95 (both from BD biosciences, San José, 
CA), and YN/1.7 (Takei 1985) respectively.  When necessary, E36 cells were sorted for 
high uniform expression of all the transfected genes (FACS sort was performed by the 
University of Massachusetts Medical School Flow cytometry core personnel). 
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2.5 Mass Spectrometry 
 
All the mass spectrometry experiments were performed by the staff of the mass 
spectrometry core at the University of Massachusetts Medical School.   
 
  Polyacrylamide gel bands were excised from silver stained gels for mass spectrometry.  
Cos-7 cells were collected after twenty-four hours transient transfection, centrifuged at 
300 xg and pellets lysed in chilled Tris buffered saline 0.5% DOC 1% NP-40 with a 
protease inhibitor cocktail (Complete mini, Roche, Indianapolis, IN).  Cold lysates 
obtained were centrifuged at 15,000 rpm in a tabletop microfuge and supernatants were 
passed through a 0.22 µm column (SpinX, Corning, Corning, NY).  Filtrates were subject 
to immunoprecipitation overnight at 4°C with 20 µL Sepharose protein A (GE 
Healthcare, Piscataway, NJ), which had been previously bound to purified anti-GFP 
rabbit polyclonal antibody (300 ng/sample, Invitrogen, Carlsbad, CA).  Beads were 
washed three times with the lysis buffer described above, resuspended in Laemmli 
loading buffer (New England Biolabs, Ipswich, MA), and ran on 10 % SDS-PAGE with 
Tris-Glycine running buffer (Ornstein 1964).  Silver staining was performed following 
manufacturer’s instructions (Bio-Rad, Hercules, CA). 
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  The bands excised corresponded to the putative spliced size (lower band) in cells 
transfected with a construct encoding GFP-SI-RecA mini-intein-CNFEKL-HAtag, or the 
pre-spliced version: GFP-SICNFEKL-HAtag.  Samples were first reduced and alkylated 
with Iodoacetamide to protect Cysteines.  After a cyanogen bromide digestion (CNBr) it 
should yield the C-terminal DELYKSICNFEKLYPYDVPDYA peptide, which 
encompasses the splice junction and therefore is appropriate to ascertain splicing fidelity.   
 
  Peptides were analyzed on an Axima CFR instrument (Shimadzu, Columbia, MD) in 
reflectron mode, a Matrix-assisted laser desorption/ionization (MALDI) quadrupole ion 
trap (QIT) time-of-flight (TOF) analyzer.  The resulting spectra were amplified to find 
the peak corresponding to the C-terminal DELYKSICNFEKLYPYDVPDYA peptide 
which has an expected m/z of approximately 2742.26 Thomson, as predicted using the 
MS-Digest in ProteinProspector 4.0.6 software (University of California). 
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2.6 Radiolabeling Experiments 
 
2.6.1 Pulse-chase 
 
E36 cells were cultured overnight with 2 µg/mL doxycycline in RPMI-1640 10% FCS in 
150 mm
2
 flasks.  Cells were trypsinized, washed with PBS and resuspended in RPMI-
1640 without L-Methionine or L-Cysteine (SIGMA, St Louis, MO).  Cells were starved 
in this medium for 20 minutes and [
35
S]-L-Met/Cys mix was added (100 µCi/million 
cells, EasyTag, Perkin Elmer, Waltham, MA) for 3 minutes.  Cells were transferred to an 
ice bath and centrifuged at 300 xg for 5 min at 4 C, labeled media was removed and cells 
were resuspended in chase media (RPMI-1640 10% FCS with excess L-Methionine and 
L-Cysteine).  Aliquots were collected at the indicated times, centrifuged at 300 xg and 
pellets lysed in chilled Tris buffered saline 0.5% DOC 1% NP-40 with a protease 
inhibitor cocktail (Complete mini, Roche, Indianapolis, IN).  Cold lysates were 
centrifuged at 15,000 rpm in a tabletop microfuge and supernatants were passed through 
a 0.22 µm column (SpinX, Corning, Corning, NY).  Filtrates were subject to 
immunoprecipitation overnight at 4°C with 15 µL Dynabeads protein G (Invitrogen, 
Carlsbad, CA), which had been previously bound to HA-7 monoclonal anti-HA tag 
antibody (300 ng/sample, SIGMA, St Louis, MO).  Beads were washed three times with 
the lysis buffer described above, resuspended in loading buffer (XT buffer with reducing 
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agent, Bio-Rad, Hercules, CA), and ran on 10 % bis-tris SDS-PAGE with MOPS running 
buffer (50 mM MOPS 50 mM Tris 1 mM EDTA 0.1% SDS, 5 mM sodium bisulfite).  
Gels were dried and exposed to a phosphor storage screen (GE Healthcare, Piscataway, 
NJ).  Screens were scanned using a Typhoon trio imager (GE Healthcare, Piscataway, 
NJ), and bands were analyzed with ImageJ software (NIH, USA).  Pre-spliced and 
spliced bands contained fewer methionine and cysteine residues than the full length intein 
bands, hence their density measurements were adjusted accordingly.  For the GFP-RecA-
HY constructs the pre-spliced or spliced species contained three cysteines and five 
methionines; whereas the unspliced intein had four cysteines and nine methionines, 
therefore the adjustment factor was sixty-two percent, and it was applied to the unspliced 
intein band intensity value obtained from Image J.  In the case of the GFP-PRP-NP 
constructs the pre-spliced or spliced species contained no cysteines and seven 
methionines; whereas the unspliced intein had two cysteines and seven methionines, 
therefore the adjustment factor was seventy-eight percent. 
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2.6.2 Continuous labeling 
 
Uninduced E36 cells were starved as described above, and grown in the presence of label 
(25 µCi/million cells [
35
S]-L-Met/Cys mix, EasyTag, Perkin Elmer, Waltham, MA) and 
doxycycline.  Aliquots were collected at the indicated times and transferred to tubes 
containing excess methionine and cysteine in an ice bath. Samples were processed as 
described above. 
 
 
2.7 Antigen Presentation Assays 
 
Expression of the lentivirally transduced antigen constructs in E36 cells was induced at 
different times by adding serially diluted doxycycline to cells growing in 96 well plates at 
10
5
 cells/well in triplicate to final concentrations ranging from 1,000 ng/mL to 8 ng/mL.  
Antigen presentation was stopped by transferring cells to an ice bath for FACS staining 
or—for hybridoma assays—by adding brefeldin A to 1 µg/mL (GolgiPlug, BD 
biosciences, San José, CA). 
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2.7.1 Immunofluorescent staining 
 
Cells were trypsinized and stained with 300 ng 25-D1.16 in 30 µL PBS containing 2% 
FCS and 0.01% sodium azide (flow cytometry buffer) on ice followed by a wash step and 
staining with 150 ng Alexa Fluor 647 goat anti-mouse IgG (Invitrogen, Carlsbad, CA).  
Cells were analyzed on a FACSCalibur (BD biosciences, San José, CA) flow cytometer. 
The results were analyzed with FlowJo software (Tree Star, Ashland, OR). 
 
 
2.7.2 Hybridoma assays 
 
10
5
 hybridoma cells/well were added to opaque white, clear bottom 96 well plates 
containing E36 cells induced for different times in triplicates.  Cells were co-cultured in 
the presence of brefeldin A for sixteen hours.  After centrifugation in an Allegra tabletop 
centrifuge (Beckman Coulter, Indianapolis, IN), dry pellets were lysed with 20 µL 
passive lysis 5X buffer (Promega, Madison, WI), and luciferase activity was measured 
with the Luciferase Assay System (Promega, Madison, WI) on a POLARstar OPTIMA 
luminometer (BMG Labtech, Ortenberg, Germany).  100 µL luciferase substrate were 
injected per well and readings were taken for 12 seconds on a well by well basis. 
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2.7.3 HY-specific T cell response assay 
 
Cell surface presentation of K9L-D
b
 complexes was quantified by co-culturing female 
HY TCR-transgenic splenocytes with E36 cells induced for different lengths of time in 
the presence of brefeldin A and then quantifying TNFα production by intracellular 
cytokine staining assays (Murali-Krishna et al. 1998). The response was measured as % 
TNFα
+
 gated on CD8
+
 T3.70
+ 
cells. The anti-mouse TNF alpha antibody and the HY 
TCR clonotypic antibody T3.70 were from eBioscience, San Diego, CA.  The anti-mouse 
CD8α (clone 53-6.7) was from BD biosciences, San José, CA. 
 
 
2.8 Clustal W Multiple Sequence Alignment 
 
The alignment data shown in Figure 1.3 were obtained using the ClustalW2 (Thompson 
et al. 1994) tool at the following server address on the World Wide Web: 
http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2  
Alignment parameters: EBLOSUM62 matrix, gap penalty 12, extend penalty 2.  
Results: 23.1% identity, 34.8% similarity. 
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2.9 Mathematical Analysis 
 
GraphPad Prism (GraphPad Software, La Jolla, CA) was used to fit exponential decay 
curves to the densities of the gel bands from pulse-chase experiments shown in Figures 
3.7 and 3.8.  The splicing rate constants on Table 6.3 were derived from these fittings.  
KinTek Explorer (Johnson et al. 2009b; Johnson et al. 2009a) was used to model the  
kinetics of expression, splicing, epitope processing, and transport, using the model shown 
in Figure 6.1.  All steps except k5 were modeled as first order processes. k1 and k6 
represent the translation rate for intact intein and pre-spliced constructs.  Values were 
obtained by fitting densitometry values or GFP fluorescence values (Figures 6.2 and 6.3).  
A process with rate equal to k1 replenishing the mRNA pool was included to simulate a 
constant mRNA supply.  k2 represents the splicing rate, determined from the pulse-chase 
data in Figure 3.8 or 3.9.  k3 represents the degradation rate of spliced or pre-spliced 
protein.  The value was obtained from fitting the densitometry or GFP fluorescence data 
(Figures 6.2 and 6.3).  k4 represents the rate of peptide epitope generation after degrading 
the source protein and MHC I loading . Its value is unknown, although there are in vitro 
studies in the literature (Cascio 2001).  We were able to vary this value over a wide range 
(0.001 – 1 h
-1
) with little effect on the Pre-spliced to Intein presentation ratio.  k5 
represents the delay due to MHC-peptide trafficking from the endoplasmic reticulum to 
the cell surface, and is modeled as a fixed time delay, added to the time scale of the 
kinetic simulation before plotting in Figure 6.4.  Varying k5 within a range of literature 
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values (Table 6.3) did not significantly change the predicted presentation ratios shown in 
Figure 6.3.  The loss of surface MHC I complexes by re-internalization was found to be 
around 0.02 h
-1 
by pulse-chase in a study using dendritic cells (Kukutsch et al. 2000).  
Varying this surface complex turnover rate (k8 in Figure 6.1) from 1.5 to 5 h
-1 
in our 
model did not significantly affect the predicted Pre-spliced to Intein presentation ratios 
shown in Figure 6.3, and hence it was not explicitly included in the model. 
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CHAPTER III: INTEINS CAN SPLICE IN MAMMALIAN CELLS 
 
 
3.1 Introduction 
 
Inteins display self-splicing capabilities even in vitro in purified preparations.  This 
strongly suggests that no other cellular factors are required for splicing to occur.  For this 
reason it was believed that splicing could be achieved in mammalian cells despite the 
inteins originating from bacteria or fungi.  There is one example in the literature (Ozawa 
et al. 2000) where an intein—in this case a split DnaE intein from the cyanobacterium 
Synechocystis species—had been expressed in mammalian cells and splicing had indeed 
taken place.  It was nevertheless necessary to ascertain the splicing capability of the 
inteins to be used for splitting the epitopes that will be measured in antigen presentation 
assays. 
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3.2 Screening for Splicing 
 
For this purpose, inteins were cloned into mammalian expression vectors interrupting the 
GFP sequence.  Inteins were inserted downstream of glycine 128 and upstream of 
aspartate 130, removing isoleucine 129 (N-terminus…VNRIELKG-Intein-
DFKEDGNIL…C-terminus).  Splicing was scored by measuring fluorescence in E36 
cells transfected transiently. 
 
.  It is worth noting that three inteins from different species failed to splice when tested in 
this fashion (Saccharomyces cerevisiae Vacuolar Membrane H
+
 ATPase 1 [VMA1], 
Cryptococcus neoformans PRP8, and Mycobacterium leprae RecA).   
 
  When the Mtu RecA and Pch PRP8 mini-inteins were tested (kind gifts from Henry 
Paulus at the Boston Biomedical Research Institute, Watertown, MA; and Stephanie 
Pöggeler at Georg-August-Universität, Göttingen, Germany) GFP fluorescence was 
observed in the wild-type intein transfected cells, whereas cells transfected with a 
splicing mutant (N3 mutant, in which the N3 domain sequence TxxH was mutated to 
TxxL) did not show a fluorescent signal.  The data for Mtu RecA is shown in Figure 3.1. 
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Figure  3.1  Splicing of the Mtu RecA mini-intein.  Flow cytometry dot plots of Cos-7 
cells transiently transfected for twenty-four hours with plasmids encoding GFP split by 
the mini-intein sequence.  The mini-intein was inserted downstream of glycine 128 of 
GFP and upstream of aspartate 130, removing isoleucine 129 (N-
terminus…VNRIELKG-Intein-DFKEDGNIL…C-terminus).  The wild-type intein is the 
Mtu RecA mini-intein (Gangopadhyay et al. 2003), and the mutant intein is an N3 
domain mutant in which TPDH was mutated to TPDL.  
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  Once the splicing capability had been ascertained, constructs were made in which model 
epitopes were intervened by the intein sequence and fused to GFP in order to monitor 
expression, and to S8L as a control splicing-independent epitope.  An HA tag was placed 
at the C-terminus to facilitate immunoprecipitation. 
 
 
3.3 Extein Flanking Residues 
 
It was found through trial and error, that the presence of hydrophobic amino acids on the 
N-terminal splicing junction greatly hindered splicing.  This was the case when S8L was 
placed immediately N-terminal of the intein’s cysteine at the N-extein-intein junction: 
splicing was hampered by the C-terminal leucine in S8L.  Isoleucine also caused splicing 
to become inefficient.  As shown in Figure 3.2, most of the immunoprecipitated material 
was recovered in the full-length unspliced band after transient transfection of Cos-7 cells 
with a construct encoding GFP-SI-Mtu RecA mini-intein-CNFEKL-HA tag.  In order to 
maintain splicing, a linker was introduced between S8L and the inteins: DEYK for the 
RecA constructs and GSFWEK for the PRP8 constructs.  The pre-spliced versions also 
contained these linkers, but no inteins.  Thus, the pre-spliced constructs were identical to 
their intein-containing counterparts after the splicing reaction had occurred. 
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Lane:     1       2       3      4       5       6 
Figure 3.2  Isoleucine in the N-terminal Splicing Junction is Detrimental for 
Splicing.  SDS-PAGE and autoradiogram after pulse-chase and immunoprecipitation 
with anti-GFP antibody of lysates made from either 293T or Cos-7 cells transiently 
transfected with a construct encoding GFP-SI-Mtu RecA mini-intein-CNFEKL-HA tag.  
The top bands correspond to the full-length unspliced construct and the bottom bands to 
the spliced product (arrow).  Lanes one and two: pulse; lanes three and four: one hour 
chase; lanes five and six: two hour chase.  Odd numbered lanes: 293T cells; even 
numbered lanes: Cos-7 cells. 
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3.4 Fidelity of Intein Splicing 
 
In order to confirm the product of the splicing reaction was identical to the pre-spliced 
construct, the corresponding bands were excised from silver stained gels and processed 
for mass spectrometry as described in the methods section.  This comparison was made 
between a construct encoding the Mtu RecA mini-intein splitting a modified S8L peptide 
(GFP-SI-Mtu RecA mini-intein-CNFEKL-HA tag) and its pre-spliced counterpart (GFP-
SICNFEKL-HA tag).  
  The online digestion software tool within Prospector (http://prospector.ucsf.edu, 
University of California, San Francisco) was used to generate cleavage sites by cyanogen 
bromide and the mass upon charge (m/z) values of the corresponding ionized peptides.  
Figure 3.3 shows the prediction software output.  Because the cysteines were protected 
with iodoacetamide, the expected peptide that would verify the splicing reaction was 
correct—DELYKSICNFEKLYPYDVPDYA—would be carbamidomethylated (-CH2- 
SH + I-CH2-CONH2 → -CH2-S-CH2-CONH2; i.e. cysteine + Iodoacetamide → S-
carbamidomethyl cysteine), and therefore the expected m/z is 2742 Thomson for the 
mono-ionized form.  
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Considered modifications: | Carbamidomethyl (C) | 
Digest Used: CNBr Max. # Missed Cleavages: 1 User AA Formula 1: C2 H3 N1 O1 
Minimum Digest Fragment Mass: 800 Maximum Digest Fragment Mass: 4000 
Minimum Digest Fragment Length: 5 
pI of Protein: 5.4 Protein MW: 28961 
Amino Acid Composition:  A9 C3 D20 E17 F13 G22 H9 I13 K21 L22 M6 N14 P12 Q8 R6 
S11 T16 V19 W1 Y14 
1  MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT  
61  LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL  
121  VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA  
181  DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYKS  
241 ICNFEKLYPY DVPDYA  
 
m/z 
(mi) 
m/z 
(av) 
Modifications Start End Sequence 
1190.5953 1191.3399  80 89 (h)KQHDFFKSAM(Met->Hsl)(P) 
1486.8516 1487.7905  220 234 (h)VLLEFVTAAGITLGM(Met->Hsl)(D) 
2685.2429 2687.0156  235 256 (h)DELYKSICNFEKLYPYDVPDYA(-) 
2742.2644 2744.0678 1Carbamido 
methyl 
235 256 (h)DELYKSICNFEKLYPYDVPDYA(-) 
 
Figure 3.3  Mass Spectrometry Digest Prediction Results.  Output from the 
ProteinProspector version 5.10.1 Proteomics tools for mining sequence databases in 
conjunction with Mass Spectrometry experiments.  MS-Digest tool was used to obtain 
m/z prediction values after inputting the expected splicing product (GFP-SICNFEKL-HA 
tag).  The key peptide DELYKSICNFEKLYPYDVPDYA that determines a correct 
splicing reaction is italicized.  (mi), monoionized; (av), average; m/z, mass upon charge 
(in Thomson [1 Thomson = 1.036426 x 10
-8
 kgC
-1
]).  Hsl, homoserine lactone. 
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  As shown in Figure 3.4 bottom panel, there are peaks in the intein sample very close to 
the predicted values for the key peptide DELYKSICNFEKLYPYDVPDYA (2,742 
Thomson) whose presence confirms a correct splicing reaction.  The intein sample was 
contaminated with some detergent as reflected by the cluster series in the spectra, but the 
presence of the 2742 peptide was evident.  This confirms both the identity of the lower 
band as the spliced product and the precision of the cleavage and relegation reaction.  
Therefore, the splicing reaction did take place as expected in mammalian cells expressing 
intein constructs. 
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Figure 3.4  MALDI-TOF spectra of pre-spliced and intein bands.  Comparison 
between a construct encoding the Mtu RecA mini-intein splitting a modified S8L peptide 
(GFP-SI-Mtu RecA mini-intein-CNFEKL-HA tag) and its pre-spliced counterpart (GFP-
SICNFEKL-HA tag).  Top panel: Pre-spliced, middle panel: intein, bottom panel: intein 
zoomed into m/z region of interest.  The 2427 peak is apparent in both samples. 
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  The splicing efficiency of the Mtu RecA and the PchPRP8 mini-inteins was acceptable 
(Figure 3.1), but the intein flanking residues could be an issue (Figure 3.2), therefore it 
was imperative to find epitopes that could accommodate the requirements for efficient 
splicing, namely contain a cysteine (for RecA) or a serine (for PRP8)—which is 
necessary for the C-terminal splicing junction—and have no hydrophobic residues 
adjacent to the N-terminal splice junction.  Of course, having an antigen presentation 
readout amenable for the epitope in question is paramount.  The influenza A virus PR8 
strain nucleoprotein 366-374 ASNENMETM (Cerundolo et al. 1991), and the murine 
male epitope SMCY 738-746 KCSRNRQYL (Markiewicz et al. 1998), both H-2D
b
-
restricted, fulfilled these requirements. 
 
  Another aspect related to the splicing fidelity is the stability of the spliced product.  In 
order to confirm this, GFP levels in cells transiently transfected with plasmids encoding 
the RecA mini-intein fused to GFP (GFP-RecA-HY) construct and its pre-spliced 
counterpart were measured after treating them with the protein synthesis inhibitor 
cycloheximide at 50 mg/mL (Morimoto et al. 1967).  As shown in Figure 3.5, the 
products of the intein splicing reaction in vivo were as stable as the pre-spliced protein.  
The approximate half-life was twelve hours in both cases. 
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Figure 3.5  Measurement of Splicing products stability.  Comparison of the stability of 
GFP fusions in E36 cells transiently transfected with plasmids encoding the RecA mini-
intein fused to GFP (GFP-RecA-HY) construct and its pre-spliced counterpart were 
measured after treating them with the protein synthesis inhibitor cycloheximide at 50 
mg/mL. GFP MFI fourteen hours post-transfection.   
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3.5 Construct Description 
 
The final version of the constructs used from here on as shown in Figure 3.6 was 
subcloned into a lentivirus expression vector (a modified version of pTRIPZ, Open 
Biosystems, Lafayette, CO) which contained two promoters: a CMV minimal promoter 
followed by tetracycline operator sequences in tandem, and a ubiquitin promoter.  The 
CMV minimal promoter drives the expression of the insert when a reverse tetracycline 
transactivator encoded downstream of the ubiquitin promoter is bound to the tetracycline 
analogue doxycycline (Gossen & Bujard 1992).  Thus, once cells were transduced, a 
single provirus encoded both the expression cassettes described above, and upon addition 
of doxycycline, expression from the CMV minimal promoter commenced.  The insert 
expression in this system proved to be very tightly controlled as no expression could be 
detected in the absence of doxycycline either by measuring GFP fluorescence or by anti-
HA immunoprecipitation and SDS-PAGE after metabolically labeling the infected cells.  
In contrast with the classical repressor system, the transactivator system allowed 
expression to be gradually controlled by increasing amounts of doxycycline, displaying a 
relatively broad dynamic range (Figure 4.1).  
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Figure 3.6  Schematic of the lentiviral constructs.  Inserts used to transduce the E36 
antigen presenting cells.  Note that the product of the pre-spliced construct is the same as 
generated by intein splicing.  The positions of the class I epitopes SIINFEKL (S8L), 
KCSRNRQYL (K9L), and ASNENMETM (A9M) are shown relative to GFP, HA tag, 
and the two different inteins.  The black horizontal bars between boxes represent short 
linkers.  
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3.6 Splicing Kinetics 
 
The kinetics of intein splicing in vivo were assessed by pulse-chase.  E36 cells infected 
with the lentiviral constructs described in Figure 3.6 were subjected to a short metabolic 
labeling and the label was chased for increasing time periods.  After immunoprecipitation 
with anti-HA or anti-GFP antibodies and SDS-PAGE two major bands were observed 
corresponding to the predicted molecular weights of the spliced and unspliced constructs.  
As expected, no splicing was observed in cells infected with the N3 mutant versions of 
either intein; at the latest time point all the immunoprecipitated protein co-migrated with 
the unspliced intein band (Figure 3.7).  The splicing kinetics were substantially faster for 
the Pch PRP8 infected cells than for the Mtu RecA infected cells, as revealed by 
quantification of band densities after pulse-chase (Figures 3.8 and 3.9).  In the case of 
Pch PRP8 infected cells, even when a short three minute pulse was applied, a large 
fraction was already in the spliced form (Figure 3.8).  This was in stark contrast to the 
Mtu RecA infected cells, in which virtually no splicing took place until 20 minutes after 
labeling had ceased.  This difference in splicing kinetics will prove useful in establishing 
whether presented epitopes are preferentially drawn from proteins shortly after their 
translation: if the contribution to presentation were mainly from species translated within 
a very short period from their degradation, the Pch PRP8 intein infected cells would 
show higher presentation levels compared to their pre-spliced counterpart than the Mtu 
RecA infected cells, since splicing and therefore generation of the epitope would be a 
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rare event in recently synthesized Mtu RecA intein proteins by virtue of the slower 
splicing kinetics.   
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Figure 3.7  The N3 mutant versions of either intein do not splice.  Autoradiogram 
after SDS-PAGE and anti-GFP immunoprecipitation of lysates from GFP-Rec-HY 
lentivirus infected E36 cells subjected to [
35
S]-Met/Cys pulse label followed by a “cold” 
chase.  The unspliced intein is indicated with a black arrowhead, and the spliced version 
with an open arrowhead. 
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Figure 3.8  Splicing Kinetics of the Pch PRP8 intein.  Autoradiogram after SDS-PAGE 
and anti-HA immunoprecipitation of lysates from GFP-PRP-NP lentivirus infected E36 
cells pre-treated with epoxomicin (5 µM, 2h) and subjected to [
35
S]-Met/Cys pulse label 
followed by a “cold” chase.  The unspliced intein is indicated with a black arrowhead, 
and the spliced version with an open arrowhead.  On the bottom: densitometry 
quantification of the bands on the autoradiogram above.  
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Figure 3.9  Splicing Kinetics of the Mtu RecA intein.  Autoradiogram after SDS-PAGE 
and anti-HA immunoprecipitation of lysates from GFP-Rec-HY lentivirus infected E36 
cells pre-treated with epoxomicin (5 µM, 2h) and subjected to [
35
S]-Met/Cys pulse label 
followed by a “cold” chase.  The unspliced intein is indicated with a black arrowhead, 
and the spliced version with an open arrowhead.  On the bottom: densitometry 
quantification of the bands on the autoradiogram above. 
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  Given the kinetics observed for intein splicing, it appears likely that the slowing splicing 
intein (RecA) will introduce a delay in the generation of the spliced product.  This would 
be equivalent to slowing down the appearance rate of the protein substrate for epitope 
production.  If we consider comparing epitope production from intein containing 
constructs to epitope production from pre-spliced constructs, this extra process should be 
taken into account and corrected for, since at early time points the difference in levels of 
pre-spliced versus spliced protein will likely be significant.  In order to correct for this 
factor, a computer model was utilized to quantify the delay in the generation of spliced 
protein as time goes by.  The model and the conclusions derived from it are presented in 
Chapter VI of this dissertation. 
 
 
3.7 Outstanding Questions and Future Applications 
 
I have shown in this chapter that inteins can in some cases splice in mammalian cells 
when produced from expression cassettes.  The splicing has been shown to occur at 
different rates depending on the nature of the intein itself as well as on the flanking 
exteins.  There are however a few outstanding questions and possible applications that 
could be addressed in the future.  
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  Although only a very limited number of inteins have been tested, it is likely that other 
inteins will also be able to splice in mammalian cells.  This prompts the question of what 
the kinetics of splicing of different inteins would be.  It would be interesting if a set of 
inteins with gradually faster or slower splicing kinetics could be obtained.  With such a 
set, a more robust correlation may be obtained between splicing rate and presentation of 
splice-dependent epitopes.  In addition, more slowly splicing inteins could help rule out 
more definitely the possibility that the split epitope is generated before fusion protein 
acquires a completely folded and functional state. 
 
  In this dissertation mini-inteins have been used instead of full-length inteins.  This is 
advantageous in this case because it makes the constructs considerably smaller while 
retaining the splicing activity of the intein.  There are other situations however, in which 
it would be interesting to use inteins to deliver cargo.  For example, the homing 
endonuclease coding sequence that has been deleted in the constructs shown here, could 
be instead replaced with a reporter gene, and the intein fused to a sequence encoding a 
protein of interest.  Thus, after the fusion protein is synthesized the intein with the 
reporter protein would be excised from the protein of interest.  This would be useful in 
situations where one wants to use the reporter gene to obtain a precise estimate of a gene 
of interest expression, but a fusion protein encompassing the protein of interest and the 
reporter protein is not functional or is not targeted to the appropriate compartment.  The 
current systems utilized for this purpose are based on dual promoters, bicistronic mRNAs 
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or on the 2A peptide system.  All these systems are problematic in that the stoichiometry 
of the two proteins encoded is not even and it may vary under different circumstances.  
For example, in situations of cellular-stress IRES-dependent translation can be enhanced 
while cap-dependent translation is inhibited (Fernandez et al. 2001; Lewis et al. 2008).  
Dual promoter systems use a different promoter for each of the transcripts often leading 
to uneven expression.  The 2A peptide system (Szymczak et al. 2004) relies on short 
peptides derived from the picornaviridae family that cause ribosomal skipping and 
ultimately the peptide bond is not formed while translation continues 3’ of the mRNA 
(Donnelly et al. 2001).  Of these systems, the 2A peptide system is the only one where 
even stoichiometry of the reporter protein and protein of interest can be achieved, 
although some fusion proteins can be observed (Provost et al. 2007).  It is not known 
whether the proposed intein system for tandem protein expression would be more 
efficient than the 2A peptide system, and therefore it remains as a possible alternative. 
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CHAPTER IV: ANTIGEN PRESENTATION OF SPLICING-DEPENDENT 
EPITOPES 
 
 
Lentivirus-infected E36 cell populations were either sorted by FACS or positively 
selected using magnetic beads.  Populations with similar GFP MFI after maximal 
induction were recovered.  For the Pch PRP8 constructs, the infection efficiency was low 
and matched expression clones were isolated by limiting dilution.  In an effort to quantify 
the levels of presentation in cells infected with intein encoding viruses so that they could 
be compared to their pre-spliced counterparts, measurements were made using either T 
cell hybridomas or the 25.D1-16 monoclonal antibody which recognizes the S8L epitope 
in the context of H-2K
b
 (Porgador et al. 1997).  It soon became apparent that there were 
substantial differences in presentation even between cell clones infected with the same 
virus or in different experiments.  This variability would be detrimental for our purpose 
of making accurate comparisons, and therefore appropriate controls were sought after in 
order to minimize it.  As a first attempt to normalize the antigen presentation 
measurements, the GFP mean fluorescent intensities (MFI) were examined (Figures 4.1 
and 4.2).   
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Figure 4.1  Dox titratable GFP production.  GFP MFI measured by flow cytometry in 
cells treated with serial dilutions of doxycycline for twenty-four hours.  Top: cells 
infected with GFP-PRP-NP or GFP-NP.  Bottom: cells infected with GFP-Rec-HY or 
GFP-HY. 
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  The magnitude of the GFP MFI and the kinetics of GFP accumulation were somewhat 
different when comparing pre-spliced to intein constructs.  This can probably be 
attributed to clonal or population differences, since the lentiviral copy number in the 
genome can vary.  Nevertheless, valid comparisons could be made between intein and 
pre-spliced expressing cells by selecting doxycycline concentrations that yielded similar 
GFP MFIs.  In addition, an internal control was built into the antigen constructs that 
allowed comparisons within the same cell: measuring the splicing dependent epitopes 
(HY or NP) relative to a splicing-independent epitope—S8L—which controls for 
potential clonal variation in other processes involved in antigen presentation, such as 
components of the ubiquitin proteasome pathway, transporters, or MHC class I chain 
synthesis. 
 
  The control epitope S8L presentation however, is H-2K
b
-restricted, as opposed to the H-
2D
b
-restricted presentation of both the intein-dependent epitopes, HY and NP, hence it 
was important to monitor H-2K
b
 and H-2D
b
 surface expression to ensure comparable 
levels in cells infected with the intein versus pre-spliced construct encoding viruses.  
Flow cytometry measurements were made regularly to monitor this.   
 
  Figure 4.3 shows that the presentation of S8L on H-2K
b
 was also titratable with varying 
doxycycline concentrations.  A dose response pattern was observed after induction of the 
constructs’ expression using serial dilutions of Dox for twenty-four hours followed by 
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surface staining with 25.D1-16 and flow cytometry, or by a hybridoma assay in the 
presence of brefeldin A.  This experiment validated the use of S8L as a control since the 
range of doxycycline concentrations at which S8L presentation displayed a linear range 
was compatible with the doses used for NP or HY assays (Figure 4.3). 
 
  The presentation of HY, NP, and S8L epitopes was inhibited by the specific proteasome 
inhibitor epoxomicin (Sin et al. 1999) as shown in Figure 4.4, indicating that after 
splicing the resulting protein is turned over via the classical ubiquitin-proteasome 
pathway.    
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Figure 4.2  Splicing dependent epitope presentation twenty-four hours after 
induction. Presentation of NP epitope measured by 12.64-Luc hybridoma assay (top) in 
cells infected with GFP-PRP-NP or GFP-NP vs. GFP MFI, or of HY epitope (bottom) 
measured by TNFα ICS in cells infected with GFP-Rec-HY or GFP-HY.  
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Figure 4.3  Dox titratable S8L presentation. Presentation of S8L epitope on H-2K
b
 
twenty-four hours after induction measured by flow cytometry (top) in cells infected with 
GFP-PRP-NP or GFP-NP and stained with 25.D1-16, or (bottom) in cells infected with 
GFP-Rec-HY or GFP-HY and used as APCs for an RF33-Luc hybridoma assay.  
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Figure 4.4  Splicing dependent epitope presentation is abrogated by proteasome 
inhibition.  Presentation of NP epitope (top) vs. [Doxycycline] in cells infected with 
GFP-PRP-NP with or without 5 µM epoxomicin six hours after induction; or presentation 
of HY epitope (bottom) vs. [Doxycycline] in cells infected with GFP-Rec-HY or GFP-
HY four hours after induction.  
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  Representing the splicing-dependent epitope relative to S8L—as a control for 
expression and presentation differences—over a range of Dox concentrations yields a 
scatter plot that can be fitted to a straight line (Figure 4.5).  The slopes of such lines 
represent the level of splicing-dependent epitope presentation relative to the level of 
control epitope presentation.  The values of these slopes were used as a normalized figure 
reflecting the levels of presentation that can be used to compare presentation between 
cells transduced with intein or pre-spliced encoding viruses. 
 
  At steady state, twenty-four hours after induction, the slopes were almost identical when 
comparing intein versus pre-spliced both for Pch PRP8 and for Mtu RecA (Figure 4.5).  
In other words, the presentation of the splicing-dependent epitope was as efficient as the 
one that did not require splicing.  Therefore, mature proteins are by no means a negligible 
source of MHC class I presented epitopes.  This also clearly points at a minor or non-
existent contribution from DRiPs to presentation at steady-state.  
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Figure 4.5  Splicing dependent epitope presentation relative to control presentation. 
Presentation of NP epitope (top) vs. S8L epitope in cells infected with GFP-PRP-NP or 
GFP-NP or presentation of HY epitope (bottom) vs. S8L epitope in cells infected with 
GFP-Rec-HY or GFP-HY twenty-four hours after induction.  Regression lines are shown.   
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CHAPTER V: PRESENTATION KINETICS 
 
 
In the previous chapter the presentation levels at steady state were shown to rely heavily 
on mature proteins as opposed to DRiPs.  This begs the question of whether the 
postulated importance of DRiPs in the early phases after viral antigen expression is 
actually true.  The presence of a Dox-inducible promoter in the viral constructs used 
allowed time course measurements of antigen presentation on MHC class I as described.  
As before, measurements of both the splicing-dependent and the control splicing-
independent epitope presentation were made and the data represented as the slopes of the 
regression lines obtained after plotting these two parameters.   
 
  The comparison between pre-spliced and Pch PRP8 intein infected cells showed that 
even as early as two hours after induction, the difference in presentation slopes was 
small, and as the induction time increased the difference between intein and pre-spliced 
was reduced until it was negligible (Figure 5.1). 
 
  In the case of the infections with viruses encoding the Mtu RecA construct or the pre-
spliced counterpart, the situation was slightly different: there was virtually no 
presentation from the cells infected with the intein construct encoding virus at the two 
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hour time point, and even at the four hour time point the difference with the presentation 
levels from the pre-spliced was substantial.  It took up to twelve hours for the 
presentation levels from pre-spliced and intein to be equal (Figure 5.2). 
 
  The results from the cells infected with the Mtu RecA construct encoding virus could 
lead to the interpretation that DRiPs are the major contributor in the early phase of 
antigen expression and although turnover from mature proteins does contribute to 
presentation, its contribution is only appreciable long after antigen expression has 
commenced.  However, the fact that presentation from the Pch PRP8 construct did occur 
very early on and at a substantially high level points at an alternative interpretation: there 
is a delay in the generation of the peptide epitope from the time of protein synthesis in the 
constructs that contain an intein by virtue of the fact that the splicing reaction occurs at a 
certain rate and the epitope is not formed until splicing is completed.  Therefore the 
amount of substrate available for degradation and presentation at the early times after 
expression induction is expected to be lower for the intein containing constructs than for 
the pre-spliced constructs, and this will be reflected on lower presentation levels from the 
intein containing constructs early after protein synthesis starts.  This interpretation is 
consistent with the fact that the differences observed in presentation levels at the early 
time points seem to correlate with the splicing kinetics; in other words the differences 
between pre-spliced and intein for the rapidly splicing intein (Pch PRP8) were smaller 
than for the intein that splices more slowly (Mtu RecA).  In order to ascertain whether 
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this explanation is plausible it was necessary to estimate what the expected differences in 
peptide epitope availability would be for pre-spliced and intein containing constructs 
along time.  Since the splicing kinetics have been described for these two inteins, the 
expected rate of appearance of the spliced product could be factored into a mathematical 
model to obtain a prediction of the expected difference in presentation between pre-
spliced and intein containing constructs at any given time.  
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Figure 5.1  Time course of A9M presentation from Pre-spliced, intein and splicing 
mutant. Measurements and linear regression of surface presentation of the A9M epitope 
versus the S8L epitope in cells infected with GFP-PRP-NP or GFP-NP for the different 
times shown.  A9M measured by 12.64-Luc hybridoma assay, and S8L measured by 
25.D1-16 staining and flow cytometry.  
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Figure 5.2  Time course of K9L presentation from Pre-spliced, intein and splicing 
mutant. Measurements and linear regression of surface presentation of the A9M epitope 
versus the S8L epitope in cells infected with GFP-Rec-HY or GFP-HY for the different 
times shown.  K9L measured by TNFα ICS, and S8L measured by RF33-Luc hybridoma 
assay.  
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CHAPTER VI: MODELING PRESENTATION AT EARLY TIME POINTS 
AFTER TRANSLATION 
 
 
The question of whether the differences in presentation levels observed in the previous 
chapter between pre-spliced and intein at the early time points can be attributed to the 
delay in the generation of the epitopes by splicing requires a precise prediction of what 
the presentation levels would be if DRiPs did not contribute to presentation when splicing 
rates were factored in.  Mathematically modeling the processes involved in MHC class I 
antigen presentation could provide such predictions, and a comparison between the 
observed data and the predicted values would allow to determine what the contribution to 
MHC class I presentation of DRiPs versus mature functional proteins is.  The KinTek 
Explorer application was used to generate the model.  This software is designed to model 
chemical reactions after mixing the initial reagents, but the processes can be written in 
such a way that they mimic biological events.  
 
  Figure 6.1 shows a scheme of the processes that have been modeled to obtain the 
predicted values of antigen presentation.  There is an initial notional pool of mRNA used 
to mimic translation in the cells after expression is induced, since any given mRNA 
molecule can be translated over and over, so it is not exhausted after a round of 
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translation.  The rates of protein synthesis and splicing are also modeled with their values 
obtained from experimental data.  The proteasomal degradation and peptide trimming are 
combined into one process to generate processing products.  Finally, MHC-peptide 
complex formation and transport to the surface as well as removal of cell surface 
complexes are also included in the model.  The synthesis and degradation rate values for 
the different species were obtained from flow cytometry experiments (Figure 6.2) or from 
constant metabolic labeling experiments (Figure 6.3).  On Table 6.3 there is a detailed 
description of each of these processes and the rate values assigned to them. 
  
  
8
8
 
 
 
 
Figure 6.1  Scheme depicting the model inputted into KinTek Explorer software for data fitting.  The different processes 
and constants are described on Table 6.3. 
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Figure 6.2  Data from cells infected with GFP-NP (Pre-spliced) or GFP-PRP8-NP 
(Intein) encoding viruses used for model fitting in KinTek explorer.  Flow cytometry 
experiments measuring GFP content per cell (GFP mean fluorescence intensity).  Lines 
are the result of fitting the KinTek explorer model to the observations (symbols).  
Symbols represent the mean of at least three independent experiments ± SD. 
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Table  6.1: MFI data from flow cytometry experiments. 
Time (h) Pre-spliced Intein 
2 3.7 4.4 
3 5.3 8.2 
6 15 25.2 
24 68.8 100 
 
Table 6.1  MFI data from flow cytometry experiments.  % maximum GFP mean 
fluorescence intensity (MFI) data from E36 cells transduced with GFP-NP or GFP-PRP-
NP constructs.  The N3 mutant of the PRP8 construct is minimally fluorescent, thus the 
intein GFP MFI values were used to obtain the rates on Table 6.3.  Averages of at least 3 
independent experiments. 
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Figure 6.3  Data from cells infected with GFP-HY (Pre-spliced) or GFP-RecA-HY 
(Intein) encoding viruses used for model fitting in KinTek explorer.  A, Constant 
metabolic labeling experiments.  Autoradiograms after anti-HA immunoprecipitation at 
different times after expression induction and SDS-PAGE.  Unspliced intein band: black 
arrowhead, and spliced product band or Pre-spliced band: open arrowhead. B, KinTek fit 
(curves) of the band densities in A (symbols).  Symbols represent average values of three 
independent experiments. 
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Table 6.2:  Band densitometry data from continuous labeling experiments. 
Time (h) Full-length intein Spliced intein Pre-spliced 
1 8 8 11 
1.5 20 10 22 
2 31 18 38 
2.5 40 26 49 
3 40 35 60 
3.5 38 46 68 
4 38 56 66 
4.5 40 61 64 
5 37 62 75 
5.5 35 64 79 
 
Table 6.2  Band densitometry data from continuous labeling experiments.  E36 
transduced with the GFP-RecA-HY construct.  Values represent % maximum band 
density from SDS-PAGE autoradiograms (see Methods).  Averages of three independent 
experiments. 
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Table 6.3: Parameters from KinTek explorer simulation experiments. 
Value 
Reaction Constant   RecA-HY PRP-NP 
Intein synthesis k1 0.91 h
-1(a)
 0.17 h
-1(b)
 
Pre-spliced synthesis k7 0.69 h
-1(a)
 0.13 h
-1(b)
 
Full-length Intein degradation  k6 0.39 h
-1(a)
 0.06 h
-1(b)
 
Pre-spliced degradation k3 0.31 h
-1(a)
 0.07 h
-1(b)
 
Intein Splicing k2 0.72 h
-1(c)
 5.42 h
-1(c)
 
Spliced product degradation k3 0.31 h
-1(a)
 0.07 h
-1(b)
 
Epitope Processing  k4 0.001 – 1 h
-1 (d)
 
MHC I complex transport k5 45-90 min
(e)
 
 
Table 6.3  Parameters from KinTek explorer simulation experiments. GFP-HY and 
GFP-RecA-HY constructs.  The source of the values is detailed below. 
a) KinTek fit of densitometry data from Figure 6.3 and Table 6.2 
b) KinTek fit of GFP fluorescence data from Figure 6.2 and Table 6.1  
c) GraphPad Prism k value from fitting exponential decay curves to pulse-chase data 
(Figures 3.3 and 3.4) 
d) This range was obtained from KinTek’s FitSpace computation (Johnson et al. 2009a). 
It shows there is no effect of this process on the presentation ratio over a very wide range 
of values.  
e) A 45-90 minute delay from epitope processing to cell surface presentation was 
estimated.  Values within this range are reported in the literature (Zhang et al. 2011; 
Hurtado et al. 2011).  In a study using mouse fibroblasts (Zhang et al. 2011), the half time 
of K
b
 trafficking through the ER was around 30 minutes, with completion in 2 hours.  
Another study with human cells (Hurtado et al. 2011) showed it took 35-60 min for 
MHC-I complexes already in the Golgi and ER to reach the cell surface. 
 94 
 
 
  The model includes synthesis, splicing, processing, and presentation steps (Figure 6.1), 
with rates derived from the literature, our experiments (Figures 3.3, 3.4, 6.2, and 6.3), or 
a range of values derived from the KinTek software fit (Table 6.3).  For GFP-RecA-HY 
the lag in presentation of the splicing-dependent epitope shortly after induction (Figure 
5.2) could be entirely accounted for by the delay in post-translational generation of the 
epitope due to the splicing reaction (Figure 3.9).  Moreover, if this interpretation is 
correct, a slower kinetic of early presentation would be less apparent with an intein 
construct that spliced more rapidly (Figure 3.8), just as it was observed (compare GFP-
RecA-HY, Figure 5.2, with the faster-splicing GFP-PRP8-NP, Figure 5.1). 
 
  All in all, no evidence has been found of a substantial contribution from DRiPs to the 
presentation of epitopes from cells infected with viruses encoding the model constructs, 
even at early time points.  Thus I conclude DRiPs are not a preferential source of peptides 
for antigen presentation. 
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Figure 6.4  Time course and in silico predictions.  Presentation from cells expressing 
the pre-spliced vs. the intein constructs (Left: GFP-RecA-HY; right: GFP-PRP-NP) as a 
function of Dox induction time.  Observed points were calculated as the quotient of the 
slopes of the regression lines fitted in Figures 5.1 and 5.2, and plotted as mean ± SEM of 
at least three independent experiments.  Predicted curves were obtained from the 
described KinTek Explorer simulation experiments. 
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CHAPTER VII: DISCUSSION 
 
 
7.1 Results in the Context of the Literature 
 
The results of the experiments presented in this dissertation did not confirm the outcome 
predicted by the DRiPs model (Yewdell et al. 1996): that the class I presentation of 
epitopes derived from mature functional species should have not been detected, or at least 
it should have been significantly smaller in magnitude to the presentation from species 
derived from DRiPs.  Considering the properties of the model constructs described in this 
dissertation, the DRiPs model would predict a significantly lower presentation from the 
intein constructs than from the pre-spliced constructs.  The steady-state data (Figure 4.2) 
clearly show there is indeed substantial presentation of the splicing dependent epitopes, 
and that the presentation levels on the cells infected with the intein-containing viruses is 
not different from the presentation levels on the cells infected with the pre-spliced 
construct viruses.  Furthermore, early after antigen expression is induced the differences 
in presentation can be fully explained by the delay in the post-translational generation of 
the splicing dependent epitopes, both for a fast splicing (Pch PRP8) and a slow splicing 
(Mtu RecA) intein (Figure 6.4). 
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  Most of the data supporting the DRiPs model relies on global protein synthesis 
inhibition.  The approach described in this dissertation, on the other hand, is based on 
model substrates.  By introducing the intein catalysis requirement for epitope formation I 
aimed at removing DRiPs from the equation.  It is however very difficult if not 
impossible with today’s technology to ascertain that every protein species with a spliced 
epitope is properly folded, since establishing protein conformation using classical means 
such as circular dichroism, nuclear magnetic resonance or crystallography would not be 
practical.  Even considering this caveat and the possibility that in some instances a 
polypeptide with a spliced epitope could be triaged as defective and enter the DRiPs pool, 
the absolute lack of contribution by DRiPs observed with this system would have been 
unexpected if DRiPs were the exclusive or dominant source of peptides for MHC class I 
antigen presentation. 
 
  The results presented here however, are consistent with earlier experiments in which 
mature proteins loaded into the cytosol readily contributed to MHC class I antigen 
presentation (Okada & Rechsteiner 1982; Moore et al. 1988; Grant et al. 1995).  The 
results in this dissertation not only confirm these previous findings, but extend them 
significantly by providing quantitative information about the contribution from the 
mature functional species of a given protein versus that from species of this same protein 
that are degraded before intein catalysis takes place; likely because of translation or 
folding mistakes.  What is more, these experiments led to the quantification of the 
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contribution to antigen presentation from mature proteins that are synthesized by the 
presenting cell—as opposed to proteins supplied externally like in the earlier 
experiments—in a situation analogous to a viral infection.  The earlier experiments with 
exogenous antigens could not exclude that the process was highly inefficient, nor whether 
the antigen that was presented came from defective molecules (e.g. denatured ones) in the 
inoculum.  Therefore, while earlier experiments suggested that the cellular machinery has 
indeed the capacity to process and present mature proteins when externally provided in 
large amounts, this dissertation provides evidence supporting the degradation of 
endogenous mature proteins as a major source for MHC class I antigen presentation. 
 
 
7.2 On the Linkage between Protein Synthesis and MHC Class I Presentation 
 
The data provided in support of the DRiPs model and the data presented in this 
dissertation are clearly opposing.  As described in the introduction chapter, much of the 
data supporting the DRiPs model relies on global protein synthesis inhibition.  This 
approach is a dangerous one, since the collateral effects of stalling protein synthesis are 
manifold and thus control experiments must be carefully designed to ensure the effects 
observed after inhibition are not artificial. 
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  In one of their experiments (Qian, Reits, et al. 2006), cells were infected with 
recombinant vaccinia virus (rVV) encoding a protein fused to an ovalbumin derived class 
I epitope (SIINFEKL), and surface MHC class I-SIINFEKL complexes were measured. 
When these cells were treated with the reversible proteasome inhibitor MG132 three 
hours post infection, and two hours later with the protein synthesis inhibitor 
cycloheximide while MG132 was washed off, a recovery in presentation even in the 
presence of cycloheximide was observed.  This was ascribed to a burst in presentation 
from DRiPs that had accumulated during the MG132 treatment, although peptides from 
turnover of mature protein could have accumulated as well, but the authors assume the 
peptides generated from turnover in two hours would be insignificant.  It is worth noting 
however, that it took one hundred minutes to start observing an increase in MHC-
SIINFEKL and two hundred minutes to increase up to a modest level.  It also took one 
hundred minutes from the initial rVV infection time until surface complexes are first 
observed, presumably because time is needed for DNA transcription, mRNA translation, 
peptide generation, and class I complex transport to the cell surface.  Considering that 
cells had been under MG-132 treatment for two hours there should have been 
considerable DRiPs accumulation; one would expect class I presentation to have occurred 
much more efficiently than in the initial phase of the infection, since high levels of 
mRNA were already present and translated substrates (DRiPs) should have accumulated, 
and yet they observed only a slow and moderate increase in surface MHC-SIINFEKL 
complexes.   
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  This suggests that the treatments applied may be affecting cell physiology and antigen 
presentation in additional ways that may confound the interpretation of the results.  While 
cells were under cycloheximide treatment, processes other than peptide generation may 
be affected if they necessitate de novo protein synthesis, which would make it difficult to 
estimate if and how much peptide production does depend on protein synthesis.  Newly 
synthesized class I heavy chains associate with the ER chaperone calnexin (Degen & 
Williams 1991), which in turn associates with TAP.  The binding of beta-2 microglobulin 
is stabilized by peptide, and allows the complex to be released from calnexin 
(Rajagopalan & Brenner 1994).  When beta-2-microglobulin is not present, class I heavy 
chains remain bound to calnexin (Rajagopalan & Brenner 1994) until they are eventually 
degraded, and the heavy chain-beta-2-microglobulin complex is very unstable in the 
absence of peptide (Sugita & Brenner 1994) 
 
  Therefore, a plausible alternative explanation for the observation that surface MHC 
class I complexes cease to appear after protein synthesis is inhibited could be that the 
complex formation requires de novo synthesis of class I heavy chain and beta-2-
microglobulin molecules.  After some time in the absence of new protein synthesis, the 
pre-existing heavy chain and beta-2-microglobulin would form class I complexes and 
would exit to the Golgi or be degraded (Rajagopalan & Brenner 1994); no further 
complexes would be formed even with a stable peptide supply from protein turnover. 
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  This situation is reflected in the mentioned experiments (Qian, Reits, et al. 2006): upon 
MG132 wash and cycloheximide addition there is a small increase in MHC-SIINFEKL 
complexes that plateaus shortly afterwards.  Moreover, the retardation observed in class I 
trafficking to the cell surface originally attributed to a diminished supply of peptides in 
the presence of protein synthesis inhibitors (Schubert et al. 2000), could in fact be 
accounted for by a requirement for de novo synthesis for complex formation. 
 
  Similarly, in experiments where cells were treated with ricin (Grant & Rock 1992) or 
cycloheximide (Donohue et al. 2006) before being exposed to exogenous native antigen 
(which obviously does not require synthesis by the cell), class I cross-presentation was 
abrogated.  The main control that I have found absent from the cited experiments is 
aimed at ruling out the possibility that steps downstream in the pathway from peptide 
generation may be affected if they require protein synthesis.  Data in the earlier literature 
pointing at such a possibility exists as described in the introduction of this dissertation, 
therefore it is likely that the MHC class I antigen presentation results obtained in 
experiments where protein synthesis inhibitors have been used are flawed and represent 
an artifact. 
 
  
 102 
 
 
  The TAP mobility study described in the introduction concluded that the majority of the 
TAP substrates were derived from newly synthesized proteins (Reits et al. 2000).  The 
authors observed that in the presence of cycloheximide only thirty percent of the peptide 
transporting activity remained.  This was attributed to an imminent reduction in peptide 
supply due to the decrease on the DRiP pool resulting from exposure to cycloheximide.  
However as discussed above, protein synthesis inhibition could also have an effect in 
presentation by preventing newly synthesized MHC class I molecules from being 
receptive to peptide.  This possibility is hard to distinguish from a bona fide effect on 
peptide supply.  Nevertheless the TAP mobility experiments presented a great 
opportunity to resolve this issue.  The laboratory where these experiments were 
performed has shown proficiency in the synthetic antigenic peptide microinjection 
technique.  Had they microinjected peptide at different concentrations and in the presence 
or absence of cycloheximide treatment, a comparison could have been made in terms of 
TAP mobility, thus confirming or ruling out an effect of global protein synthesis 
inhibition on MHC class I loading and on cell surface presentation.  A similar control 
experiment was indeed performed but only at a single peptide concentration of 10 mM in 
the microinjection needle, and only in the presence of cycloheximide.  This concentration 
is no doubt overwhelming and it should have been titrated down in order to make the 
experiment informative with regards to the question of whether there is an effect of 
global protein synthesis inhibition on MHC class I loading. 
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7.3 Examples of DRiPs-derived Epitopes 
 
There are examples in the literature where the generation of individual epitopes appears 
to be dependent on de novo synthesis of their source protein.  In the context of the LCMV 
infection (Khan et al. 2001), an epitope derived from the nucleoprotein showed a strong 
dependence on protein synthesis.  It should be noted that there are seven known class I 
epitopes derived from the LCMV nucleoprotein in the mouse, and only one was linked to 
protein neosynthesis.  It is not known whether all others were analyzed, but they could 
have been and most likely they were, therefore the vast majority of the epitopes derived 
from NP did not show a dependency on neosynthesis. 
 
  In the case of the Epstein-Barr virus, because of the special characteristics of its EBNA 
proteins, the possible dominance of DRiPs as a source of peptides for MHC class I 
presentation (Mackay et al. 2009) cannot be generalized, for the native form of this 
antigen may not be degraded via the ubiquitin-proteasome pathway.  This is an unusual 
fact that could be a means of viral immune evasion.  There is evidence that the 
degradation of the EBNA protein does not occur through the ubiquitin-proteasome 
pathway once the infection is established (Levitskaya et al. 1997; Sharipo et al. 1998; 
Heessen et al. 2002; Hoyt et al. 2006).  Even mutants in which the glycine-alanine-rich 
domain (GAr) of EBNA-1 has been deleted (Daskalogianni et al. 2008) degradation 
might not proceed mainly through the ubiquitin-proteasome pathway, although this is 
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controversial.  It has been pointed out that EBNA1 is in fact at least partly degraded in 
infected B cells through autophagy instead of through the usual ubiquitin-proteasome 
pathway (Leung et al. 2010).  It is obvious that if the degradation of the mature protein by 
the proteasome is prevented with or without GAr, then most of the class I presentation 
will be forced to derive from DRiPs, therefore the apparent linkage between translation 
and presentation in this case is due to the special circumstances surrounding the 
degradation of the EBNA proteins  
 
 
7.4 DRiPs as a Preferential Source of MHC class I Ligands 
 
With regards to the mechanisms that would allow for DRiPs to be used preferentially 
there have been several models.  In one case an increase in mis-aminoacylated tRNAs 
upon viral infection or exposure to interferon was reported (Netzer et al. 2009).  This 
would lead to a significantly greater DRiP rate due to amino acid misincorporation, thus 
contributing to an increase in class I antigen presentation.  Therefore, this mechanism 
would not imply that DRiPs are preferentially presented, but rather that their abundance 
increases with infection.  It is however a noteworthy fact that in the lengthy literature 
concerning the identification of MHC class I epitopes, there is not a single case of amino 
acid misincorporation in the epitope itself, which seems inconsistent with protein species 
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with high rate of misincorporation being the principal source of peptides for presentation.  
Also, a study where proteins with mutations were assessed for their antigen presentation 
potential showed that in spite of the mutants’ actual misfolding, their degradation was 
only slightly faster, and epitope production was not significantly enhanced (Golovina et 
al. 2005). 
 
  Because the model system described in this dissertation deals with defined epitopes in 
frame, it is not possible to quantify the contribution of out of reading frame peptides 
(Malarkannan et al. 1999) or the non-AUG initiation phenomena (Schwab et al. 2004) 
described in the introduction chapter.  The preponderance of DRiPs may be magnified as 
a consequence of the effects that viral infections have on the fidelity of mRNA 
translation.  Although I have used lentiviral vectors to express the constructs described 
here, the possible effects that the infection may have on the translational machinery will 
most likely be minimal, since the viruses used are non-replicative and they integrated in 
the cellular DNA well before the antigen presentation experiments were conducted.  
Thus, in this experimental system the contribution to MHC class I antigen presentation 
from alternative reading frames or non-AUG initiation cannot be established.  It is 
possible that non-AUG initiation derived products might be an important contributor to 
MHC class I presentation under the circumstances discussed in the introduction chapter, 
namely viral infection and cellular stress.  Nevertheless, this mechanism cannot explain a 
preferential use of peptides derived from DRiPs for MHC class I antigen presentation, 
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rather it might make peptides derived from DRiPs more likely to be presented by virtue 
of their increased abundance in a situation of viral infection or cellular stress.  However, 
whether this increased contribution is significant is still to be determined. 
 
  Thus, a scenario where the relative contribution to MHC class I presentation from 
different sources is determined by the abundance of their degradation products, in 
contrast with a different scenario where there exists a specialized mechanism or 
compartment preferentially supplying peptides from defective proteins, would be in 
agreement with the views put forth in this dissertation. 
 
  Looking back at the results shown here, the products of the spliced inteins were 
relatively stable, and there was nevertheless abundant presentation of the epitopes they 
contained.  This might seem counterintuitive at first glance, but if we consider the 
expression levels were high, even at a very small degradation rate, a significant supply of 
peptides could be contributed to the class I presentation pathway.  In this regard it would 
be informative if we could compare constructs with different stability or a construct 
whose half-life could be modulated, such as the one described recently (Dolan et al. 
2011). 
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  To summarize, sixteen years after the DRiPs hypothesis was introduced, almost all of 
the supporting data is indirect and could be explained in alternate ways. 
 
 
7.5 Direct Measurements by Mass Spectrometry 
 
The contribution from mature proteins to the MHC class I pathway of antigen 
presentation was questioned in studies using SILAC where no correlation was observed 
in the presented epitope levels and the abundance of the corresponding source proteins in 
cells (Milner et al. 2006).  The interpretation that this absence of correlation pointed at a 
predominance of DRiPs as a source for presented peptides is flawed, since it is not the 
abundance of the source protein but rather the turnover rate that determines the peptide 
availability to the pathway (Pratt et al. 2002).  In other words, a very abundant protein 
that is very slowly turned over would generate many potentially presentable peptides per 
unit of time.  When they did compare the turnover rate with HLA-derived peptide 
abundance (Milner et al. 2006) they interpreted that there was evidence for a DRiP-
centric model: a biphasic pattern in the production of presented peptides was observed, 
and the early presentation wave was attributed to DRiPs.  However, only seven 
peptides—three clear ones—displayed this biphasic pattern attributable to DRiPs, and 
most of their source proteins were part of multimeric complexes and likely the 
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appearance of peptides derived from them in the first phase could have been due to the 
degradation of the proteins before assembly into complexes even though they were not 
necessarily defective.  This phenomenon is known to occur with members of multimeric 
complexes, e.g. the CD3 components (Alarcon et al. 1988).  Finally and most important, 
although it was not pointed out in the paper, the data showed that the majority of 
presented peptides were labeled even ninety-six hours after the free labeled amino acids 
were chased from the cells.  Unfortunately, in this study (Milner et al. 2006) the number 
of proteins for which a turnover rate could be obtained was rather low.  It is expected that 
with newer technology this number could be increased substantially. Therefore the 
generation of presented peptides was not restricted to a short-lived DRiP pool but rather 
come from more long-lived proteins which acquired their label days before degradation.  
 
  Future experiments using SILAC technology could be performed to ascertain the 
contribution of DRiPs as compared to that of mature proteins to the pool of MHC class I 
presented peptides.  By looking at mass shifts in peptides derived from proteins labeled 
with stable isotopes, it is possible to establish the proteome turnover rate.  Proteins can be 
labeled by culturing cells for sufficient time in the presence of amino acids containing a 
heavy isotope, followed by culture with unlabeled amino acids.  By sampling at intervals 
during the chase and establishing the ratio of heavy versus light peaks using mass 
spectrometry, a turnover rate can be obtained.  In fact, this kind of experiment has been 
performed and there are published databases with abundant information on many 
109 
 
 
proteins’ turnover rate determined using SILAC (Boisvert et al. 2012).  It would be a 
matter of reproducing this kind of experiment while also collecting MHC class I eluted 
peptides in order to correlate peptide abundance with turnover rates.  If a correlation 
cannot be established, the DRiPs model would be supported, and if there is a correlation, 
this would point at turnover as the major supplier of peptides for MHC class I 
presentation. 
 
 
7.6 The Pioneer Round of Translation 
 
A separate piece was added recently to the DRiPs model: the pioneer round of translation 
(Dolan et al. 2010; Apcher et al. 2011; Sébastien Apcher et al. 2012).  This potential 
source of MHC class I presented epitopes encompasses the degradation products of a 
nuclear translation round which is part of the mRNA nonsense-mediated decay (NMD) 
quality control pathway in the nucleus.  It is arguable whether these translation products 
could be DRiPs, since they are not necessarily defective or shunted by quality control 
chaperones for degradation.  This potential source is nevertheless very different from the 
one provided by the turnover of mature functional proteins, and it fits other teleological 
criteria attributed to DRiPs: the products of the pioneer round of translation seem to be 
degraded rapidly regardless of the half-life of their mature functional counterparts, and 
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they are separated from the mature proteins at the translation level, thus overriding the 
putative bias in presentation towards more abundant proteins that the DRiPs hypothesis 
predicted if the main source of peptides for MHC class I presentation were mature protein 
turnover.   
 
  As described in the introduction chapter, the NMD pathway works in conjunction with 
the pre-mRNA splicing machinery, and therefore if this were the dominant mechanism 
for coupling DRiPs to antigen presentation, it would miss so many viral products derived 
from RNAs that do not contain introns.  Although this pathway may contribute to 
presentation, it is worth noting that with the experimental constructs utilized in the report 
in question (Apcher et al. 2011), one hundred percent of the mRNAs contained a 
premature termination codon, whereas in real life situations the frequency of this 
happening would be much lower.  Thus, this overabundance of pre-mRNA substrates that 
should be recognized and targeted for degradation may have been overwhelming for the 
system, and a fraction of these RNAs with premature stop codons could have escaped 
decay and may have been transported out of the nucleus and translated in the cytosol.  As 
a matter of fact, there was a truncated product derived from one of the constructs with an 
encoded premature termination codon which was clearly detected by western blot, and 
therefore its mRNA was translated heavily and not just minimally during the pioneer 
round of translation (Apcher et al. 2011, fig.3). 
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  With regards to the intein constructs described in this dissertation, it is formally possible 
that intein splicing took place shortly after the pioneer round of translation, and therefore 
the splice-dependent epitope might derive from this source and not from protein turnover.  
This is very unlikely for two reasons: one is that the degradation of the products of the 
pioneer round of translation is believed to occur very quickly, and therefore the fraction 
of molecules that would have completed their intein splicing before degradation would be 
very small.  Another reason is that the RNAs produced from the expression cassettes in 
the constructs did not have any introns, and the pioneer round of translation seems to be 
linked to the nonsense-mediated decay mRNA pathway which requires the pre-mRNA 
splicing machinery to interact with splicing junctions.  A termination codon is recognized 
as premature as opposed to the bona fide termination codon when the exon junction 
complex is downstream of it.  Of course a round of NMD-independent nuclear translation 
that supplied substrates for protein degradation and MHC class I presentation cannot be 
ruled out, but there is no evidence yet of its existence.  In fact it is not known whether the 
pioneer round of translation produces any polypeptides at all, it may simply involve 
scanning 
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7.7 DRiPs in the Context of the Immune Response 
 
The implications of these results are discordant with the DRiPs hypothesis (Yewdell et al. 
1996).  Contribution from DRiPs might occur, but they do not seem to be an exclusive, 
preferential, or even a substantial source of peptides for presentation on MHC class I.  
According to the hypothesis, DRiPs are preferentially used by the immune system 
because a source of readily degraded proteins is required to provide peptides for class I 
presentation, thus allowing swift elimination of virally infected cells before the infection 
can spread.  Let us consider this necessity from the point of view of an in vivo immune 
response. 
 
  Immune responses dependent on CD8
+
 T cell-mediated elimination of infected cells 
require a priming phase (Bevan 1976), where the appropriate naïve clones are activated 
by professional antigen presenting cells (Huang et al. 1994)—pAPCs: dendritic cells 
(Schuler & Steinman 1985; Smith et al. 2003) and macrophages (Pozzi et al. 2005)—
before they go on to divide and generate memory and effector CD8
+
 T cells.  Effector 
CD8
+
 T cells have cytotoxic activity when they encounter any cell type that displays the 
cognate MHC class I-peptide complex (Zinkernagel & Doherty 1975).  Memory CD8
+
 T 
cells can become effectors upon encountering antigen once again. 
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  It is important to distinguish between the initial first encounter with the virus—the 
induction of the immune response—and subsequent encounters—the recall response.  
According to the DRiPs model’s teleology (Yewdell et al. 1996), the limiting factor for a 
timely elimination of infected cells is MHC class I antigen presentation.  This may be 
true during a recall response, since the memory CD8
+
 T cells would be poised to respond 
to antigens on class I on the surface of infected non-professional antigen presenting cells.  
In contrast, during the induction of the CD8
+
 T cell immune response, the potential 
effector cells would still be naïve, and other time consuming events—known as the 
priming phase—would have to take place before they can become effectors and respond 
to presented antigens on infected cells.  In the latter type of response the celerity of 
presentation by non-professional APCs does not seem to be that crucial, since the time 
required for priming far exceeds the time of a relatively slow acquisition of class I 
ligands derived from slowly turning over viral proteins in infected cells.  In the case of 
LCMV, CD8
+
 T cell-mediated interferon gamma production peaks at days four to eight, 
even after enormous doses are injected intraperitoneally (Merigan et al. 1977).  Dendritic 
cells take one to three days to present antigens derived from herpes simplex virus in the 
draining lymph node (Smith et al. 2003).  In another study, the presentation of antigens 
derived from influenza A virus inoculated into the mouse airways was first detected in 
the lymph nodes 1 day after infection, peaking at day three (Belz et al. 2004).  In 
experiments with sheep, the presence of lymphoblasts was detectable eighty hours after a 
primary infection with vaccinia virus (Issekutz 1984).  Therefore an extremely rapid 
presentation of viral antigens on MHC class I upon first encounter with a virus is 
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probably not crucial to prevent viral spread, which contradicts a major assumption 
leading to the DRiPs hypothesis. 
 
  The priming phase involves antigen capture and transport to lymphoid organs, where 
antigens are presented to naïve cells.  It has been shown that priming can occur if the 
pAPC is directly infected by the virus (Norbury et al. 2001).  However, often times 
viruses have a tropism for cells other than pAPCs, and pAPCs acquire and present 
antigen through a process called cross-presentation (Kovacsovics-Bankowski & Rock 
1995; Sigal et al. 1999), in which the antigen is folded functional protein engulfed by 
phagocytosis (Shen & Rock 2004; Norbury et al. 2004).  This process allows the priming 
of CD8
+ 
T cell responses against viruses that do not infect pAPCs.  Therefore, since cross 
presented antigens come from mature proteins, the teleological argument that DRiPs are 
needed to initiate a CD8
+
 T cell response is again flawed.   
 
  There are some viral infections, such as the vaccinia virus infection that can be very 
cytopathic and proceed with great celerity by generating large amounts of viral particles 
as early as one or two hours after exposure to the virus .  In this case the presentation of 
antigens on class I would need to occur very shortly after viral infection for infected cells 
to be killed by CTLs before viral particles spread to neighboring cells even in the context 
of a recall response.  It is noteworthy though, that neutralizing antibodies play a major 
role in the protective immune response against vaccinia (Downie & McCarthy 1958), and 
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thus containment of the viral progeny does not rely exclusively in the ability of the 
memory CD8
+
 T cells to lyse infected cells.  This is not the case in the LCMV infection, 
as it has been shown that the major players in the immunity to LCMV are CD8
+
 T cells 
(Asano & Ahmed 1996).  However, as discussed above, this infection is not as cytopathic 
and the primary CD8
+
 immune response to it proceeds more slowly.  Therefore, DRiPs 
would be more advantageous for the immune response to fast replicating viruses, keeping 
in mind the caveat that the celerity in class I presentation by non-professional APCs in a 
primary infection does not warrant a faster generation of effector CTLs. 
 
  Another important point comes from considering how many peptide-MHC class I 
complexes are sufficient to activate CD8
+
 T cells.  In the case of ovalbumin cross-
priming, the amount of SIINFEKL-H-2K
b
 complexes present in pAPCs sufficient to 
trigger the priming of an immune response is below the limit of detection of the 25-D1.16 
antibody used in the studies by Yewdell’s group.  Cytotoxic CD8
+
 T cells (CTLs) have a 
lower activation threshold than naïve cells encountering the antigen for the first time, i.e. 
even fewer peptide-MHC class I complexes will trigger a cytotoxic response. 
 
  There are somewhat diverse estimates in the literature of what the peptide-MHC 
complex density threshold might be.  Villanueva et al. 1994 showed that the number of 
peptide-MHC complexes on the cell surface was about one for every thirty-five of the 
source proteins degraded.  In a report examining the minimal epitope density necessary 
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for the lysis of target cells (Sykulev et al. 1996), the known epitope-MHC class I·TCR 
affinities were plotted against the estimated epitope densities on the cell surface of target 
cells.  A linear trend was obtained, and it was determined that the minimal peptide-MHC 
class I complexes necessary to promote lysis were between one and ten per cell.  
However, in the lysis systems used in the experiments discussed above, the epitope-MHC 
densities were between twenty and one hundred for TCR affinities with a KD in the µM 
range, which are similar to the affinities of the TCRs used in the experiments described in 
this dissertation (Willcox et al. 1999; Alam et al. 1999), except for the HY TCR which 
has a lower affinity for its peptide-MHC ligand (Ober et al. 2000) and therefore is 
expected to require a higher peptide-MHC density to trigger lysis.  To summarize, most 
likely the threshold for CD8+ T cell activation is between one hundred and a thousand.  
The affinity of the OT-I TCR that recognizes S8L on H-2K
b
 is 6 µM, and therefore the 
expected threshold in terms of epitope density should be on the lower end. 
 
  So if few complexes on the cell surface are enough—certainly below the limit of 
detection of the 25-D1.16 antibody—there is no need to go above and beyond that limit 
in the very early phases after infection in order for the CTLs to lyse target cells.  It is also 
important to realize that stable proteins with long half-lives are nevertheless continuously 
degraded, a process that starts immediately after synthesis.  Therefore, the teleological 
argument behind the DRiPs hypothesis greatly loses strength, since the small amount of 
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complexes required could be fulfilled by degradation of full-length functional proteins 
through proteasomal degradation even if their half-lives are long.   
 
  The major postulated advantage of DRiPs over mature proteins as a source of MHC 
class I presented peptides is the quick degradation of the former, which provides a large 
number of peptides shortly after protein synthesis starts.  However, most folding mistakes 
are not necessarily terminal and there is evidence describing folding and re-folding 
attempts through the interaction with chaperones (Hartl & Hayer-Hartl 2002; Goldberg 
2003; Claessen et al. 2012).  These quality control and rescue efforts take time and 
therefore work against the notion of extremely rapid degradation to build up a large 
peptide pool.  Moreover, when antigens have been made intentionally defective they are 
most often degraded relatively slowly (Golovina et al. 2005). 
 
 
7.8 Protein Degradation Kinetics and MHC class I Presentation 
 
Two opposing processes operate to determine the concentration of a protein in the cell: 
synthesis and degradation.  In order to achieve effective concentrations of viral proteins 
after infection, the balance between synthesis and degradation must be shifted towards 
synthesis during the period before steady state.  At steady state however, both processes 
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are balanced, i.e. the number of molecules that are degraded equals the number of 
molecules that are synthesized and this is independent of the degradation rate.  Therefore, 
at steady state the number of peptides generated from a protein will match its synthesis 
rate and this will be independent of whether it is a short-lived species (including DRiPs) 
or a long-lived one.  For example, a rapidly synthesized viral protein that gets degraded at 
a very low rate will be abundant at steady state, as long as its likelihood of being 
degraded remains constant.  Such a protein will still yield a high number of peptides per 
unit of time in spite of its low degradation rate, by virtue of its abundance.   On the other 
hand one should take into account that during viral infection structural proteins are 
depleted not only by degradation but also due to viral particle egress from the cell.  This 
implies that even at steady state the degradation rate will be slower than the synthesis 
rate.  This might lead to a different scenario where stable long-lived proteins could be 
rapidly synthesized, incorporated into viral particles and exit the cell at a vigorous rate.  
In this case there may be an advantage to a DRiPs-based system, but always keeping in 
mind the caveats that there are typically large pools of unassembled viral proteins in 
infected cells, that it is probably not necessary to generate a large amount of class I 
presented epitopes to achieve the desired immune response, and also the aforementioned 
fact that even long-lived proteins do get degraded at a constant rate albeit slow as soon as 
they are synthesized. 
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  While much is known about the quality control mechanisms that operate during protein 
synthesis and folding in the ER (Hartl & Hayer-Hartl 2002; Goldberg 2003; Claessen et 
al. 2012) and in the cytosol (Hartl & Hayer-Hartl 2002; Goldberg 2003; Komar 2009), 
the signals that lead to the turnover of mature proteins are still incompletely understood.  
It has been long speculated that the exposure of a hydrophobic domain might trigger 
recognition by members of the ubiquitin ligase (E3) family, leading to polyubiquitylation 
and degradation by the proteasome.  Evidence of this has been provided in yeast for the 
recognition by the ubiquitin ligase San1 (Fredrickson et al. 2011).  Oxidation damage is 
one the best documented causes of mature protein degradation (Berlett & Stadtman 
1997).  Oxidation of amino acid side chain groups, such as thiols in cysteines can lead to 
structural changes in proteins, and cellular pathways exist to prevent and even repair such 
instances (David 2004).  These structural changes may expose hydrophobic domains and 
recognition by the Hsp70/CHIP machinery may target the protein for degradation (Pratt 
et al. 2010).  Remarkably, there is some evidence, albeit in vitro, that proteasomes can 
degrade oxidized proteins independently of ubiquitylation, and again it is speculated that 
this is due to recognition of exposed hydrophobic domains (Ullrich et al. 1999; 
Shringarpure et al. 2003).  Although it seems plausible for all the reasons stated here that 
the peptide pool generated by protein turnover is sufficient for the class I system to 
monitor protein expression in the cell, a system evolved for immune sampling that is not 
linked to protein synthesis quality control but rather operates at a later stage, cannot be 
ruled out by the experiments presented in this dissertation.  Such a system would 
reconcile the postulated evolutionary need for quick and uniform sampling of synthesized 
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polypeptides with the experimental evidence shown in this dissertation that the mature 
protein pool can contribute peptides to the MHC class I presentation pathway. 
 
 
7.9 Immune Surveillance and Cancer 
 
Another scenario in which immune-mediated elimination of host cells is beneficial is 
cancer.  CD8
+
 T cells have been implicated in transformed cell elimination and MHC 
class I epitopes have been identified (van der Bruggen & Van den Eynde 2006).  Cancer 
antigens that lead to MHC class I presentation encompass those encoded by germline or 
differentiation genes as well as the products of mutations.  Of course some transformation 
events are the product of tumorigenic virus infection and the expression of viral products 
by the transformed cells can lead to MHC class I-mediated elimination.  The host’s 
tolerance mechanisms generally prevent responses against cells expressing non-mutated 
self proteins, and therefore other changes must occur in non-virally transduced cancer 
cells that make them suitable targets for CD8
+
 T cells and at the same time distinguish 
them from the normal host’s cells.  Leaving the tolerance override question aside, it is 
clear that many class I epitopes in the context of cancer are presented and CD8
+
 T cell 
responses are mounted against cells presenting them (for a referenced list see 
http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm).  
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  With regards to the subject matter of this dissertation, the question is whether the 
generation of these cancer epitopes preferentially from DRiPs would constitute an 
advantage for the immune response against cancer.  In most cases antigens either start 
being expressed or their steady state levels greatly increase as a consequence of 
transformation (van der Bruggen et al. 1991; Gaugler et al. 1994; Boël et al. 1995).  This 
situation would be different than in the context of a viral infection, since the urgency in 
preventing the spread is not as great.   A cancer cell is not like a virally infected cell, 
where the pathological cell is producing viral progeny that will spread the disease. 
Therefore, it is not essential to stop the process within hours of onset.  The cancer cells 
will be around for days to years and will have steady state levels of mature proteins.  The 
immune system could be effective in preventing the disease if it eliminated the cell or its 
progeny even months after transformation.  However, it was pointed out a few years ago 
that peptides derived from alternative reading frames—which can qualify as DRiPs—
might become more abundant when overexpression occurs (Ho & Green 2006; Yewdell 
& Hickman 2007).  Therefore, alternative reading frame encoded epitopes appear as an 
ideal candidate for the CD8
+
 T cell immune response against cancer and hence cancer 
would be one situation in which the identification of this kind of DRiPs would be 
expected.  There are a few reports of alternative reading frame derived epitopes in cancer 
situations.  A case has been described where the epitope originated from a non-AUG 
initiation event that extended the polypeptide length (Ronsin et al. 1999).  In other reports 
(Wang et al. 1996; Rosenberg et al. 2002) epitopes derived from alternative reading 
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frames elicited T cell clones that could lyse melanoma cells.  One should note however, 
there are cases in which the peptides presented are not necessarily derived from DRiPs, 
but rather from mutations at the gene level that cause frameshifts (Ripberger et al. 2003; 
Huang et al. 2004; Oh et al. 2004); in other words, the peptides are not produced due to 
mistakes in mRNA translation, but rather mutated mRNAs are produced as a result of 
mutations in transformed cells and likely derived from the transformation causative 
events, since they are observed in most cancers with similar phenotype.  All in all, it 
seems like the bona fide MHC class I epitopes derived from alternative reading frames 
identified in the context of cancer are not as numerous as one would expect if DRiPs 
were a major contributor to the pathway, although the absence of more examples might 
be due to the difficulty of purifying, expanding and screening CD8
+
 T cell clones specific 
for these epitopes. 
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CONCLUDING REMARKS 
 
 
I have presented in this dissertation the current model for the generation of presented 
MHC class I peptides: the DRiPs model.  This model has received wide acceptance in the 
scientific community as reflected by the many publications referring to the issue, none of 
which have challenged the view that DRiPs are a major contributor to the MHC class I 
presentation pathway. 
 
  This model is based on a teleological argument, and experiments were performed after 
the hypothesis was postulated.  In the discussion chapter of this dissertation I have argued 
that there is really no need for a rapidly degraded protein pool as a source of peptides for 
MHC class I presentation for the priming of an immune response, nor for the elimination 
of infected cells by effector CD8
+
 T cells. 
 
  The experimental data in the literature aimed at providing support for the DRiPs 
hypothesis were reliant on the use of global protein synthesis inhibition, which as 
discussed can have collateral effects, and thus the interpretation of the results can be 
misleading.  Nevertheless, there are other pieces of data in the literature that seem to be in 
accordance with the DRiPs model.   
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  In order to shed light on this issue, I have described an experimental system which 
allows to quantitatively distinguish the contribution to MHC class I of peptides derived 
from proteins that have attained enzymatic function and are thus considered mature.  The 
results from my experiments clearly point at an absence of a substantial contribution to 
MHC class I antigen presentation by DRiPs.  This implies that efforts directed at 
enhancing the immune response for certain CD8
+
 T cell epitopes by targeting the source 
antigen to a DRiP compartment are probably futile and should be focused elsewhere, as 
the importance of such a compartment in the MHC class I presentation pathway has been 
exaggerated. 
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